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2 ABSTRACT
Nitric oxide (NO) generated by phagocytes at inflammation sites contributes to 
regulate immune responses through both autocrine and paracrine actions on bystander 
cells. Among the latter are dendritic cells (DCs). Little is known about regulation of DC 
function by NO, especially in the human system. In this thesis I report about the role of 
NO in two specific aspects of human DC maturation: i.e. endocytosis and ability to 
induce T cell activation. At variance with rodents, human DCs express the inducible 
isoform of the NO synthase neither when immature, nor after various treatment which 
induce DC maturation, indicating that regulation of these cells may occur only through 
exogenous NO. Exposure of DCs to NO, released by either bystander phagocytes or NO 
donors, reversed the inhibition of endocytosis induced by TNF-a. The intracellular 
accumulation of ceramide induced by TNF-a was also inhibited by NO. In addition, NO 
was found to exert an inhibitory effect downstream of the TNF-a-triggered ceramide 
accumulation, since NO donors reversed the inhibition of endocytosis induced by the 
cell-permeant C2-ceramide. I then studied the role of NO on DC ability of triggering T 
cell activation. DCs were exposed to the NO donor DETA-NO during their maturation 
process induced by treatment with TNF-a or lipopolysaccharide, or by CD40 activation. 
After exposure to DETA-NO, DCs exhibit a significantly increased ability to activate T 
lymphocytes stimulated by mycobacterial antigens. Staphylococcus aureus Cowen 
strain B, allo-antigens, or cross-linking of the CD3-T cell receptor complex. This effect 
persists after removal of DETA-NO and is due to enhanced release by DCs of soluble 
factors, in particular IL-12. All the effects described above were mimicked by the 
membrane-permeant cyclic GMP analogue, 8-Br cyclic GMP, and prevented by 
inhibition of the soluble guanyly 1-cyclase. The cGMP dependent modulation of DC
function reported here is due to a synergism between NO and the various maturation 
stimuli since neither the changes in endocytic function nor the enhanced T cell 
activation and IL-12 release were observed after DC exposure to DETA-NO only. 
These results provide the first evidence that NO acts as a co-signalling molecule 
regulating human DC response to maturation stimuli.
3 INTRODUCTION
3.1 Dendritic cells are professional antigen presenting cells
Dendritic cells (DCs) are antigen-presenting cells (APCs) possessing a unique 
ability to induce primary immune responses by capturing and transfering information 
from the outside world to the cells of the adaptive immune system. Dendritic cells are a 
heterogenous cell population, residing in most peripheral tissues, concentrated at sites of 
interface with the environment (skin and mucosae), where they represent l%-2% of the 
total cell number (Banchereau et al., 1998; Banchereau et al., 2000). In peripheral 
tissues, DCs internalise self and nonself antigens, which are then processed into 
proteolytic peptides and loaded onto major histocompatibility complex (MHC) class I 
and II molecules to be presented to T cells. Such presentation process is quite inefficient 
in peripheral DCs. However specific signals induce them entering into a developmental 
programme, called maturation, which transforms them into efficient APCs and T cell 
activators. Among these signals are bacterial and viral products, often referred to as 
danger signals, as well as inflammatory cytokines and other self-molecules, which 
induce maturation through direct interaction with specific receptors expresed on DC 
plasma membrane. The final stages of maturation are contributed by T lymphocytes, 
and are mediated by direct cell-to-cell contact and cytokines secretion, through CD40- 
dependent and -independent pathways (Bell et al., 1999).
The maturation process is characterized by changes in the efficiency of antigen 
uptake, intracellular transport and degradation, and in the intracellular trafficking of 
MHC molecules (Thery et al., 2001). In particular, DCs lose antigen-capturing ability, 
while peptide loading, as well as the half-life and delivery to the cell surface of MHC 
molecules, is increased. Surface expression of T cell costimulatory molecules also
increases. These molecular events explain how DCs become potent APCs, capable of 
activating naive T lymphocytes and initiating adaptive immune responses.
To interact with T cells, however, DCs also need to migrate out of the tissues to 
reach secondary lymphoid organs. Thus, concomitant to the modifications of their 
antigen presentation abilities, maturation also induces massive migration of DCs out of 
peripheral tissues (Banchereau et al., 2000). The basis for migration resides in the 
modified expression of chemokine receptors and adhesion molecules together with 
profound changes of the cytoskeleton organization. The scheme shown as figure 1 
highlights the most important features of DCs. By linking antigen uptake, peptide 
loading, and cell migration to the encounter of a danger signal (Gallucci et al., 2001), 
these cells restrict presentation to those antigens internalized during maturation, thus 
favoring stimulation of T cells specific for potentially pathogenic antigens 
(Guermonprez et al., 2002).
Under different microenvironmental conditions DCs can drive lymphocytes into 
distinct classes of effectors, critical for resistance to infections and tumors. Conversely, 
DCs can generate regulatory T cells that suppress activated T cells, a function of 
importance in autoimmunity and transplant rejection. Moreover, DCs are involved in 
innate immunity, they can respond to microbial challenge by producing substantial 
amounts of cytokines, such as IL-12 and interferons, which play a critical role in host 
defense. Dendritic cells also activate NK cells that rapidly kill select targets and also 
produce cytokines relevant to innate immune responses. Finally, it is becoming 
increasingly clear that DCs also capture antigens against which immunity is normally 
avoided. These include environmental proteins chronically found in the respiratory and 
digestive tracts, as well as self antigens derived from tissues exhibiting constitutive cell
turnover. The capture of these proteins in the absence of microbial perturbations allows 
DCs to control tolerance to self and “normal” environmental constituents (Mellman et 
al., 2001).
Figure 1 The life cycle of DCs
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Antigens are captured by DCs in peripheral tissues and processed to form MHC-peptide 
complexes. As a consequence of antigen deposition and inflammation, DCs begin to mature and 
migrate to lymphoid organs where, after maturation, they display peptide-MHC complexes, 
which allow selection of rare circulating antigen-specific lymphocytes. Activated T 
lymphocytes migrate and can reach the injured tissue. Helper T cells secrete cytokines, which 
permit activation of macrophages, NK cells and eosinophils. Cytotoxic T cells eventually lyse 
the infected cells. B cells, after contact with T cells and DCs, mature into plasma cells, which 
produce antibodies that neutralize the initial pathogen (from Banchereau and Steinman 1998).
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3.2 The dendritic cell: development and subsets
The diverse functions of DCs in immune regulation depend on the plasticity of 
DCs at the immature stage as well on the diversity of DC subsets and lineages. 
Immature DCs (imDCs) are continuously produced within the bone marrow from 
hematopoietic stem cells. FLT-3 ligand, and to a lesser extent GM-SCF, represent the 
key factors for DC growth and differentiation in vivo (Pulendran et al., 2001). In the 
bone marrow CD34^ hematopoietic stem cells diferentiate into common lymphoid 
progenitors (CLP) and common myeloid progenitors (CMP) (Fig 2). CD34^ CMPs 
appear to differentiate into CD34^ CLA^ and CD34^ CLA populations, which 
subsequently differentiate into CDllc^ CDla^ and CDllc^ CD la ' imDCs, respectively. 
While CDllc^ CDla^ imDCs migrate into the skin epidermis and became Langerhans 
cells, CDllc^ CD la" imDCs migrate into the skin dermis and other tissues, and become 
interstitial imDCs (Liu 2001).
The CD34^ stem cells-derived Langerhans cells and interstitial imDCs display 
different phenotypes and function (Caux et al., 1997). For example, interstitial imDCs, 
but not Langerhans cells take up large amounts of antigens by the mannose receptors 
and to produce lL-10, which may contribute to naïve B cell activation and IgM 
production in the presence of CD40 ligand and lL-2. Langerhans cells, on the other 
hand, induce CD8^ T cell-priming higher than interstitial DCs. Since in the human fetus 
and in newborn rats imDCs are present in lymphoid and nonlymphoid tissues, their 
production and diversification from CD34^ stem cells in the bone marrow appear to be a 
part of hematopoiesis, which is pathogen-independent and occurs in a steady-state. 
Based on the steady-state migration into both nonlymphoid and lymphoid tissues, and
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the ability to actively sample self-antigens, it has been proposed that imDCs play critical 
roles in peripheral tolerance by inducing CD4^ and CD8^ regulatory T cells (Liu 2001).
In addition to the two subsets of imDCs, stem cells also give rise during 
hematopoiesis to two types of DCs precursors (pre-DCs): monocytes (pre-DC 1) and 
plasmacytoid cells (pre-DC2). ImDCs, but not pre-DCs, have dendrites or veils, exhibit 
high mobility in culture, and colonize nonlymphoid tissues in the absence of 
stimulation. ImDCs express moderate levels of costimulatory molecules and induce 
moderate T cell activation in vitro. By contrast, isolated pre-DCs express very low 
levels of costimulatory molecules and do not induce significant naïve T cell activation 
in culture (Liu 2001). When kept in culture with GM-CSF and lL-4, or after 
phagocytosis of bacteria pre-DC Is differentiate into immature myeloid DCs (im-DCls). 
On the other hand, when in culture with lL-3, or following an innate immune response 
to viral stimulation pre-DC2s differentiate into im-DC2s.
DCs derived from pre-DC Is and pre-DC2s cultured with GM-CSF plus lL-4, 
and lL-3, respectively, display different functional properties after CD40 ligand 
activation. DC Is produce large amount of IL-12 and induce strong T helper type 1 (Thl) 
and cytotoxic T lymphocyte (CTL) responses, while DC2s do not produce large amount 
of IL-12, and induce Th2 responses, or the generation of IL-lO-producing CD8+ T 
suppressor cells (Rissoan et al., 1999; Ito et al., 2001). Unlike lL-3- and CD40 ligand- 
induced DC2s, which promote Th2 responses, viral-induced DC2s promote helper T 
cells to produce both IFN-y and lL-10.
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Figure 2 DCs development from hematopoietic stem cells
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CD34^ hematopoietic stem cells differentiate into common myeloid progenitors cells (CMP) 
and common lymphoid progenitors cells (CLP). The CMPs differentiate into CD34^ CLA^ and 
CD34'^ CLA late progenitor cells. While CD34^ CLA^ cells differentiate into CDl Ic^ CDla^ 
Langerhans cell precursor, CD34^ CLA cells differentiate into CDl Ic^ CD la interstitial DC 
precursors in blood. The blood CDl Ic"^  CDla^ Langerhans cell precursor migrate into the skin 
epidermis and became Langerhans cells and the CDl Ic^ CD la cells migrate into the skin 
dermis and other tissues to became interstitial DCs. The above processes of DCs development 
and diversification are antigen-independent. Without antigen/pathogen stimulation, both 
Langerhans cells and interstitial DCs may undergo a steady-state migration into the draining 
lymph nodes, where they may play a critical role in immuno tolerance. Upon microbial invasion 
and inflammation, Langerhans cells and interstitial DCs rapidly migrate into the draining lymph 
nodes. They undergo maturation and initiate primary immune response.CMP and CLP also give 
rise to myeloid pre-DC Is and lymphoid pre-DC2s in bone marrow. During bacterial and viral 
infection, pre-DC Is and pre-DC2s differentiate into DCs and initiate respectively antibacterial 
and antiviral adaptive immune responses (modified from Liu 2001).
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3.3 Induction of dendritic cell maturation and signal transduction
Dendritic cells can be activated to enter the maturation process in the presence 
of two types of signals: direct recognition of pathogens (through specific pattem- 
recognition receptors) and indirect sensing of infection (through inflammatory cytokines 
and internal cellular compounds) (Gallucci et al., 2001). Five types of surface receptors 
are reported to trigger DCs maturation: (i) cytokine receptors, (ii) Toll-like receptors 
(TLR), (iii) receptors activated by ligands expressed on T cells, (iv) FcR, and (v) 
sensors for cell death.
(i) Maturation by cytokine receptors: DCs sense danger and infections indirectly, 
through inflammatory mediators such as TNF-a and IL-IB, whose secretion is triggered 
by pathogens (Bell et al., 1999; Kalinski et al., 1999). Most of the receptors which 
trigger DC maturation are known to be expressed also in other cell types, where their 
signal transduction cascades have been analyzed in detail. I will describe a few general 
processes and then concentrate mainly on studies which specifically analyzed DC signal 
transduction.
TNF-a signaling occurs through two distinct cell surface receptors, TNF-Rl and 
TNF-R2. In vitro DC differentiation is triggered by activation of p55 TNF-Rl (Sallusto 
et al., 1995). The initial step involves binding of the TNF-a trimer to the extracellular 
domain of TNF-Rl with release from the intracellular domain (ICD) of TNF-Rl of the 
inhibitory protein silencer of death domains (SODD). Aggregated ICD is recognized by 
the TNF receptor-associated death domain (TRADD), which recruits additional adaptor 
proteins, i.e. receptor-interacting protein (RIP), TNF-R-associated factor 2 (TRAF2), 
and the Fas-associated death domain (FADD) (Chen et al., 2002). These latter proteins 
recruit to TNF-Rl various enzymes that are responsible for initiating signalling events
14
(Fig 3). In addition, two major trancription factors, NF-kB and c-Jun, are activated. In 
the case of NF-kB this involves the phosphorylation by the IkB Kinase complex 
(including IKKa and IKK|3), of the inibitor IkB, allowed by its ubiquitination and 
degradation by proteasomes. As a consequence, NF-kB then translocates to the nucleus 
and partecipates in the expression of genes necessary for DC maturation (Banchereau et 
ah, 1998).
Figure 3 TNF-a signal transduction pathway
T N F -R l
I N F
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i
Engagement of TNF-a with its cognate receptor TNF-Rl results in the release of SODD and 
formation of a receptor-proximal complex containing the important adaptor proteins TRADD, 
TRAF2, RIP, and FADD. These adaptor proteins in turn recruit additional key pathway-specific 
enzymes to the TNF-Rl complex, where they become activated and initiate downstream events 
leading for example to NF-kB activation (modified from Chen and Goeddel 2002).
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The IL-IR system is composed of a ligand-binding subunit, IL-IRI, and a signal 
transducing subunit, ILlRacP. Upon binding of IL-1, IL-IRI forms a complex with 
ILlRacP. The adaptor protein, MyD88, is next recruited to this complex, which in turn 
facilitates its association to the IL-lR-associated kinase (IRAK), via its death domain. 
After autophosphorylation, IRAK dissociates from the receptor complex and interacts 
with TRAF6. Association of TRAF6 with NF-kB-inducing kinase (NIK, a MAP 3 
kinase-related protein) leads to the activation of the IKK complex with ensuing direct 
phosphorylation of IkB, followed by dissociation and degradation of this inhibitory 
component from NF-kB.
Human DCs respond not only to TNF-a, but also to IL-lp and CD40-L with 
intracellular ceramide accumulation, as they are induced to differentiate. The ceramide- 
mediated pathway can shut down antigen capture by the DCs (Sallusto et al., 1996).
16
Figure 4 IL-IR signalling pathway
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Upon binding of IL-1, IL-IRI forms a complex with ILlRacP. This complex recruits IRAK via 
an adaptor MyD88. IRAK then becomes autophosphorylated, dissociates from the receptor 
complex, and interacts with TRAF6. TRAF6 associates with NIK. NIK activates the IkB kinase 
complex (including IKKa and IKK(3) that directly phosphorylates IkB, which allows 
dissociation and degradation of this inhibitory component of NF-kB (modified from Akira 
2001).
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(ii) Maturation by TLR: DCs mature in response to various pathogenic 
compounds, including several bacterial wall components (such as lipopolysaccharide, 
LPS), unmethylated CpG motifs, and double-stranded RNA. Most of these molecules 
are recognized by a large family of surface receptors called TLR (Medzhitov et ah,
2000). In different cells of the immune system, pathogen-associated pattern molecules 
are specifically recognized by one or by a combination of TLRs. For example, through 
binding of LPS TLR4 mediates the responses to GRAM bacteria; TLR2 is involved in 
the responses to various GRAM‘S cell wall components (including bacterial 
peptidoglycans), and to bacterial lipoproteins; TLR5 recognizes flagellin from both 
GRAM^ and GRAM bacteria; and TLR9 binds unmethylated CpG motifs (Aderem et 
al., 2000).
Dendritic cells express a subset of receptors, including TLR2, TLR3, and TLR4 
(Visintin et al., 2001; Muzio et al., 2000). The function of TLR2 has been characterized. 
It triggers DC maturation in response to bacterial peptidoglycans (Michelsen et al.,
2001), lipopeptides (Hertz et al., 2001), and mycoplasma lipoproteins (Nishiguchi et al., 
2001). TLR3 is expressed exclusively by DCs, and absent from precursors monocytes. 
Moreover, the expression of TLR3 increases dramatically during monocyte 
differentiation and decreases significantly after treatments inducing maturation. The 
TLR family is characterized by a cytoplasmic domain with high homology to the 
intracellular portion of the IL-IR family. Signalling of human TLRs occurs by the same 
transduction molecules involved in signalling through IL-IR. For example, TLR4 
engagement results in the recruitment of an adaptor molecule, MyD88, followed by the 
kinase IRAK and the subsequent steps through TRAF6 and NIK, leading to NF-kB 
activation (Akira 2001). Rescigno et al. showed that LPS-induced maturation of DCs
18
involves two signalling pathways: (a) ERK kinase for DC survival, and (b) NF-kB for 
processes involved in DC maturation: increased expression of costimulatory and MHC- 
class II molecules, release of chemokines, and migration (Rescigno et ah, 1998). More 
recently, Ardeshna et al., confirmed that NF-kB is required for LPS-induced maturation 
of human monocyte-derived DCs (Ardeshna et al., 2000). They also found that survival 
of these DCs depends on activation of the P13K. Finnally, recent results identify MyD88 
as an essential component of TLR signalling in DCs (Kaisho et al., 2001).
Not all TLRs, however, activate a MyD88-dependent signalling pathway. In the 
absence of MyD88, DC maturation induced by TLR2 and TLR9 is completely 
abolished, whereas maturation by TLR4 activated by LPS is maintained (Muzio et al., 
1998; Kaisho et al., 2001). A MyD88-independent pathway, involving MAPK and NF- 
kB, exists therefore downstream of TLR4 (Muzio et al., 1998; Akira 2001).
19
Figure 5 MyD88-dependent and -independent pathways in DC maturation
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At least two signalling pathways originate from the cytoplasmic portion of TLR4. One is the 
MyD88-dependent pathway, which subsequently activates IRAK, TRAF6, and NF-kB. This 
pathway is essential for cytokine production. The other is the MyD88-independent pathway, 
which cannot activate IRAK or TRAF6. Although the signalling molecules involved are 
unknown, this pathway can also induce NF-kB activation. This NF-kB activation cannot lead to 
cytokine induction but to induction of costimulatory molecules such as CD40, CD80, and 
CD86 in DCs (modified from Akira 2001).
(iii) Maturation by lisands expressed on T  cells. Triggering of CD40 by CD40L 
on T cells does induce DC maturation (Schuurhuis et al., 2000; Caux et al., 1994). M ost 
of the studies regarding CD40-mediated signal transduction were carried out by the use 
of B lymphocytes. Despite the impressive amount of data, however, knowledge of this 
pathways remains incomplete.
Multimerization of CD40 molecules following engagement with CD40L or 
antibodies appears as a critical initiating step for CD40-mediated signalling. Although 
the cytoplasmic domain of CD40 lacks sequences indicative of any catalytic activity, it
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can associate with members 2, 3, 5 and 6 of TRAFs. After recruitment to the CD40 
cytoplasmic tail following receptor engagement (a step that is enhanced by CD40 
oligomerization) TRAFs mediate the activation of NF-kB and MAPK family. The CD40 
cytoplasmic tail also associates constitutively with Jak 3, which becomes activated 
following CD40 engagment and leads to activation of STATs. In addition, numerous 
studies support the idea that early events in CD40 signalling involve stimulation of 
protein tyrosine kinases, including Lyn, Fyn, and Syk (Schonbeck et al., 2001). In DCs 
CD40 signalling is initiated at plasma membrane cholesterol-rich microdomains (rafts). 
TRAF2/3 and src-family protein kinases (such as Lyn) are recruited together with CD40 
to membrane rafts. TRAF2/3 initiates the activation of p38MAPK, and lyn induces ERK 
activation (Vidalain et al., 2000). p38 MAPK is required for CD40-induced IL-12 
production in DCs because these cells derived from Mkk3 (a p38 activator)-deficient 
mice fail to produce IL-12 in response to CD40 stimulation (Lu et al., 2001) (Fig 6).
T cells can induces DC maturation through CD40-dependent and -independent 
mechanisms. Indeed, triggering of Fas and OX40L on DCs by FasL and 0X40 on T 
cells respectively may induce functional maturation (Rescigno et al., 2000; Ohshima et 
al., 1997).
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Figure 6 Model of CD40-mediated signalling in human DCs.
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Initiation of signalling events requires a membrane raft reorganization triggered by engagement 
of CD40, which allows Lyn activation and TRAF2 and 3 recruitment. Lyn activation, and 
possibly that of other Src family kinases, leads to IL-1 a, IL-1 (3 and IL-lRa mRNA expression 
via a MEK/ERK pathway. p38 MAPK activation, which induces IL-12 mRNA expression, is 
probably stimulated through a TRAE-initiated pathway, and to some extent in the early phase of 
CD40 signalling, through a Src family kinase-dependent pathway (from Vidalain et al., 2000).
(iv) Maturation by FcR: DCs may also be activated during the endocytic process 
through the engagement of receptors to the Fc portion of immunoglobulins (FcR). In 
addition, engagement of most FcR, including FcyRI and FcyRIII, by immune complexes 
or specific antibodies, induces DC maturation (Geissmann et ah, 2001; Jurgens et al., 
1995; Regnault et al., 1999). This process requires the FcR-associated y-chain that 
contains an immunoreceptor tyrosine-containing activation motif (ITAM). Tyrosine
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phosphorylation of this motif may initiate DC maturation. FcsRI triggering in 
Langherans cells induces phosphorylation of the tyrosine kinase syk and Ca'^ '*' 
mobilization. It has been recently demonstrated that FcyR engagement in mouse DCs 
induces syk and ERK phosphorylation, and that syk is necessary to immune complex 
induced-DC maturation (Guermonprez et al., 2002).
(v) Maturation by cell death: cell death can be sensed as a danger signal by DCs. 
Shi et al. showed that cell injury releases adjuvant compounds that enhance T cell 
responses (Shi et al., 2000). Two studies showed that necrotic, but not apoptotic, cell 
death induces mouse and human DC maturation in vitro (Sauter et al., 2000; Gallucci et 
al., 1999), although another study found that apoptotic bodies may induce DC 
maturation (Rovere et al., 1998). One should be careful in interpreting these results, 
however, because LPS, mycoplasma contamination (Salio et al., 2000) or CD40L 
expression by apoptotic bodies (Propato et al., 2001) could be responsible for DC 
maturation. The nature of the DC activating compounds is in fact still unclear.
The list of processes proposed to induce DC maturation is still long. It includes 
nucleotides, such as ATP and UTP, acting through purinergic receptors (Gallucci et al.,
2001) and hsps, including gp96, hsp90, and hsc70, released by necrotic cells, whose 
mechanism is still unclear (Basu et al., 2000; Singh-Jasuja et al., 2000). Although CD91 
has recently been identified as a gp96, hsc70, and hsp90 receptor, its role in DC 
activation has not yet been explored. Hsp60 and hsc70 activate macrophages through 
CD 14 and/or TLR (Vabulas et al., 2001; Ohashi et al., 2000; Asea et al., 2000; Kol et 
al., 2000), but receptors engaged on DCs have not yet been characterized. Recent data 
show that release of high mobility group 1 (HMGBl) protein from necrotic, but not 
apoptotic cells can induce an inflammatory response, acting as a diffusible signal of
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unprogrammed death to bystander immune cells and activating DCs (Scaffidi et ah, 
2002; Rovere, personal communication).
It is unlikely that all these pathways for the induction of DC maturation are 
redundant. In addition to result in functionally distinct DC populations, different 
activation signals may either act synergistically or regulate each other. For example, 
human TGF-B-untreated DCs are activated by LPS or TNF-a; this does not occurs with 
TGF-B-treated monocyte-derived DCs, which instead require a CD40-dependent signal 
to acquire high T cell stimulating activity (Geissmann et al., 1999).
3.4 Antigen uptake in dendritic cells
Dendritic cells were long belived to display low endocytic activities. Therefore, 
because of their inability to take up antigens, and in spite of their high MHC class II 
expression, they were not considered as APCs. This idea lasted until regulation of the 
endocytic ability of DCs was discovered. Bone marrow-derived DCs at an early stage of 
development were shown to internalize particulate antigens, an activity that in mature 
DCs became weak or inactive (Steinman et al., 1995). The establishment of an in vitro 
system that allows human DCs to be mantained in culture without affecting their 
immature phenotype, i.e., with efficient antigen uptake and processing, has provided an 
important tool to gain insights into basic mechanisms governing differentiation (Sallusto 
et al., 1995). Tissue DCs capture pathogens, infected cells, dead cells, or their derived 
products to use them for antigen presentation. Interestingly, pathogen recognition and 
uptake are in many cases accompanied by activation/maturation of DCs (Guermonprez 
et al., 2002).
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3.4.1 Receptor-Mediated Endocytosys
During receptor-mediated endocytosis, the uptake of macromolecules occurs 
through specialized regions of the plasma membrane, termed coated pits. The process is 
initiated by a signal in the cytoplasmic tail of stimulated receptors, recognised by a 
family of adaptors responsible for the recruitment of clathrin lattices and for the 
formation of clathrin-coated endocytic vesicles (Slepnev et ah, 2000). A large number 
of receptors destined to be endocytised by this procedure are expressed by imDCs.
Mouse imDCs express receptors for immunoglobulins: FcyRI, FcyRII, and 
FcyRin, which mediate the uptake of immune complexes or opsonized particles 
(Esposito-Farese et al., 1995; Fanger et al., 1996). Human monocyte-derived DCs 
express mainly FcyRII and FcaR (Geissmann et al., 2001). The neonatal MHC class I- 
like FcR for IgG was also found on human monocytes-derived DCs (Zhu et al., 2001). 
Another receptor of the immunoglobulin superfamily competent for antigen 
presentation, named immunoglobulin-like transcipt (ILT)-3, was found in imDCs. 
(Celia et al., 1997). Moreover, immature DCs express complement receptor CR3 and 
CR4, but not CRl and CR2 (Reis e Sousa et al., 1993).
Heat shock proteins (hsps) derived from tumor cells or infected cells, are known 
to stimulate antigen-specific T cell responses in vivo. Hsp70 and gp96 bind APCs and 
are internalized through specific membrane receptors (Castellino et al., 2000; Amold- 
Schild et al., 1999). Scavenger receptors (SRs) are cell surface glycoproteins defined by 
their potential to bind chemically modified low-density lipoproteins. SRs play an 
important role in host defense because they are implicated in internalization of various 
bacteria. Dendritic cells express at least one type of SR; CD36 (class-B-SR), involved 
in the uptake of apoptotic bodies (Platt et al., 1998).
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C-type lectins share a carbohydrate recognition domain and bind ligands in a 
Ca^^-dependent manner. Dendritic cells express several transmembrane C-type lectins, 
including macrophage-mannose receptor (MMR) (Sallusto et al., 1995) and DEC205 
(Jiang et al., 1995). The MMR binds several monosaccharides as well as a wide variety 
of pathogen antigens, including yeast antigens (Ezekowitz et al., 1991), 
lipoarabinomannan (Prigozy et al., 1997), and desialylated immunoglobulins (Dong et 
al., 1999). The MMR is expressed on macrophages and on monocytes-derived DCs, but 
not on freshly isolated blood monocytes. In humans, DEC205 was only reported on 
blood DCs, and its function is not yet documented (Kato et al., 2000).
3.4.2 Phagocytosis and Macropinocytosis
Particulate and soluble antigens are efficiently internalized also by phagocytosis 
and macropinocytosis, respectively. Both processes are actin-dependent, require 
membrane ruffling, and result in the formation of large intracellular vacuoles. 
Phagocytosis is generally receptor-mediated, whereas macropinocytosis is a 
cytoskeleton-dependent type of fluid-phase endocytosis. The engagement of specific 
receptors initiating phagocytosis triggers a cascade of signal transduction, which is 
required for actin polymerization and effective engulfment. In general, the same 
receptors mediate both phagocytosis and clathrin-dependent endocytosis (Guermonprez 
et al., 2002). Immature DCs were reported to phagocytose almost any bacteria (Bell et 
al., 1999), yeast cells (d’Ostiani et al., 2000), parasites such as Leishmania major (Gorak 
et al., 1998), apoptotic and necrotic bodies (Subklewe et al., 2001). In macrophages and 
epithelial cells, macropinocytosis is transiently induced by growth factors and phorbol 
esters. In imDCs, in contrast, macropinocytosis is constitutive (Sallusto et al., 1995).
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Macropinocytosis represents a critical antigen uptake pathway allowing DCs to sample 
rapidly and non specifically large amounts of surrounding fluid.
3.4.3 Regulation of endocytosis in dendritic cells
Efficient antigen internalization is a specific property of imDCs. During 
maturation, DCs downregulate their endocytic capacity, thus limiting the range of 
antigens they are able to present after residing within peripheral tissues. Loss of 
internalization processes occurs through two independent mechanisms: downregulation 
in cell surface expression of most antigen receptors (MMR/FcR) and decrease in both 
macropinocytosis and phagocytosis (Sallusto et al., 1995; Sallusto et al., 1994). Two 
independent groups have analyzed the molecular mechanism responsible for regulation 
of endocytosis. They both found that inactivation of the small GTPases cdc42 and ra d  
blocks both macropinocytosis and phagocytosis in imDCs (West et al., 2000; Garrett et 
al., 2000). In contrast to the findings of Garrett et al.. West et al. could neither detect 
any changes in the active forms of cdc42 during maturation nor restore 
macropinocytosis in mature DCs by microinjecting constitutively active cdc42. These 
results suggest that DCs express various mechanisms for downmodulation of 
internalization.
3.5 Chemokines and the migration of dendritic ceils
Since this topic is not a subject of my thesis work, it will be described only 
breafiy. The function of DCs is intimately connected to their capacity to migrate. 
Immature DCs are recruited to the sites of infection where they are exposed to the 
stimuli that induce migration via afferent lymph to the T cell areas of secondary
27
lymphoid organs. These changes in migratory behavior have been related to changes in 
the expression of adhesion molecules and chemokine receptors that allow the cells to 
sense chemotactic gradients. For instance, when epidermal Langerhans cells are 
activated and migrate from the skin, E-cadherin is down-regulated and laminin receptors 
up-regulated (Sallusto et al., 1998).
Chemokines can be broadly divided into inflammatory and constitutive. The first 
are induced, or strongly upregulated in peripheral tissues by inflammation. The latter 
have housekeeping functions and may be involved in constitutive leukocyte traffic. The 
capacity to respond to chemokines depends on the set of chemokines receptors 
expressed by leukocytes. In DCs rapidly changing their migratory behaviour these 
receptors are tightly regulated. Immature cells express chemokine receptors, such as 
CCRl, CCR2, CCR5 and CCR6, which guide them to the site of inflammation. 
Maturing DCs downregulate expression of inflammatory chemokine receptors and 
upregulate expression of CCR7 (Sallusto et al., 1998). Up-regulation of CCR7 is 
relevant for homing of mature DCs, since the known ligands for this receptor, 
secondary-lymphoid-tissue chemokine (SLC) and the EBLl ligand chemokine (EEC) 
are produced in secondary lymphoid organs (Sallusto et al., 1998; Gunn et al., 1998). 
Recently, MDR-l-type p-glycoprotein (MDR-1) has been identified as a potential 
mediator of DC migration from the skin to the lymphatic vessels. The mechanism by 
which MDR-1 acts is still unclear. Recent data suggest in fact that MDR-1 is not a 
mediator of adhesion. Its activation might therefore be indirect. Based on its well- 
known role as a membrane transporter, MDR-1 could induce translocation of a soluble 
substrate, as yet unidentified, that regulates migration (Randolph et al., 1998).
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3.6 T cell stimulation by dendritic cells
Maturation is associated with a rapid relocation of antigen-bearing DCs to the T 
cell zone of secondary lymphoid organs. Maturation also enhances surface levels of 
costimulatory and adhesion molecules among which important ones are B7.1 and B7.2, 
which bind both CD28 and CTLA-4 on T cells. These modifications increase the T cell 
priming ability of DCs. Two signals are necessary in order to achieve full T cell 
activation: recognition of MHC-peptide complexes on DCs by Ag-specific TCRs, which 
constitutes "signal one" and interaction between costimulatory molecules expressed by 
DCs and their ligands expressed by T cells, the so-called "signal two". CD86 on DCs is 
so far the most critical molecule for amplification of T cell responses. On the other 
hand, CD28 is constitutively expressed on T cell and facilitates the initial phases of T 
cell priming, while CTLA-4 is inducible and is involved in the downregulation of T cell 
responses (Banchereau et al., 2000).
T cells can activate DCs via CD40 ligand (CD40-L)-CD40 signalling, leading to 
increased expression of CD80/CD86 and cytokine release (ILl, TNF, chemokines, and 
IL-12) (Sallusto et al., 1994; Ridge et al., 1998; Schoenberger et al., 1998; Caux et al.,
1994). Triggering of CD40 on DCs results in upregulation of 0X40 ligand (Stuber et al.,
1995). Ligation of 0X40 at the time of priming induces T cells to migrate to B cell 
areas (Brocker et al., 1999). At least in vitro, ligation of 0X40 to CD4^T cells induces 
upregulation of the chemokine receptor CXCR-5 on naïve CD4^ T cells (Flynn et al.,
1998). The ligand for this chemokine receptor is expressed in B cell follicles, which 
explains why OX40-activated T cells accumulate at this site (Gunn et al., 1998).
Mature DCs also express 4-lBB ligand (DeBenedette et al., 1997), which 
complements the function of OX40-L. 4-1BB is a costimulator expressed primarily on
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activated CD4^ and CD8  ^ T cells (Saoulli et al., 1998). 4-lB B costimulatory signals 
preferentially induce CD8  ^T cell proliferation and production of IFN (but not of IL-4) 
(Kim et al., 1998), leading to the amplification of in vivo cytotoxic T cell responses in 
graft-vs-host disease as well as in allograft rejection (Shuford et al., 1997). Whether 
OX40-L and 4 - IBB are expressed simultaneously by the same DC or separately by 
distinct DCs remains to be established.
Engagement of RANK, a member of the TNFR family, by its ligand 
(RANKL/TRANCE) expressed on activated T cells, stimulates secretion of cytokines 
like IL-1, IL6, and IL-12 by DCs. As a whole, this process results in increased DC 
survival by inhibition of apoptosis and, in turn, in enhanced proliferative T cell 
responses in mixed lymphocyte reactions. The demonstration that TRANCE is 
responsible for the CD40L-independent T-helper cell activation during viral infection 
suggests an important and specific role for this molecule during infection (Anderson et 
al., 1997; Wong et al., 1997; Josien et al., 1999).
Dendritic cell-T cell clustering is mediated by several adhesion molecules, like 
integrins 81 and 82 and members of the immunoglobulin superfamily (CD2, CD50, 
CD54, and CD58) (Hart 1997; Bell et al., 1999). Another important accessory molecule 
is DC-SIGN, i.e. the first recognized DC-restricted product that helps stimulate resting 
T cells. It has been proposed that the interaction of DC-SlGN with lCAM-3 on T cell 
can mediates the loose adhesion that takes place between DCs and T cells in the 
apparent absence of foreign antigen. Such adhesion provides the TCR an opportunity to 
scan the DC surface, searching for the small amounts of MHC-peptide ligands, which 
then activate resting T cells. DC-SIGN allows the DCs to interact temporarily with 
naïve T cells.
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Whichever the signalling molecules involved, antigen recognition leads to the 
formation of a contact zone termed the immunological synapse, rich in interacting 
adhesion and signalling molecules (Steinman 2000).
3.7 Nitric Oxide and its synthesizing enzymes
After providing a general picture of the DCs role in immunological responses 
and of their ligand-receptor regulation time has come to introduce a new participant of 
the game, nitric oxide (NO) which is the major actor of my thesis.
Nitric oxide is a free-radical gas that readily diffuses through cells and cell 
membranes where it reacts with molecular targets. Contrary to conventional 
biosignalling molecules that act only by binding to specific receptor molecules, NO 
induces its biological actions also via a wide range of chemical reactions. With its 
molecular weight of 30, NO is a small molecular mediator (Fang 1997), it has a short 
half life, between 3 and 20 seconds in aqueous and oxygen-containing solutions 
(Vladutiu 1995). Nitric oxide is a double-edge sword. Produced by mammalian cells in 
an appropriate quantities and time, it is a key signalling molecule in physiological 
process as diverse as host-defense, neuronal transmission, and vascular regulation 
(Nathan 1992; Nathan et al., 1994; Stuehr et al., 1992). On the other hand, excessive 
NO synthesis has been implicated as a causal or contributing factor to 
pathophysiological conditions including many human diseases: vascular shock, stroke, 
diabetes, neurodegeneration and chronic inflammation (MacMicking et al., 1997).
Responsible for the synthesis of NO is a family of enzymes: the nitric oxide 
synthases (NOSs), which catalyze the conversion of L-arginine to NO and L-citrulline. 
Nitric oxide synthase produces NO by oxidizing guanidino nitrogen of L-arginine,
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utilizing molecular oxygen and NADPH as cosubstrates. Two molecules of water are 
coproducts. This process involves two successive monooxygenation reactions, with the 
initial reaction yielding Nco-hydroxy-L-arginine as an isolatable intermediate (Stuehr et 
al., 1991) and the final reaction processing the hydroxylated nitrogen of NOH-ARG to 
NO (Stuehr et al., 1992). All NOS isoforms contain four prosthetic groups: flavin 
adenine dinucleotide (FAD), flavin adenine mononucleotide (FMN), iron 
protoporphyrin IX (heme), and tetrahydrobiopterin (THE). The NOS reaction is 
summarized in Fig. 7.
Figure? Biochemical pathway of NO production in mammalian cells. Two 
sequential reactions are catalyzed by NO synthase.
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NOS catalyze the NADPH- and 02-dependent five electron oxidation of L-arginine to NO and 
citrulline. When fully active the enzyme contains one equivalent each of FAD, FMN, heme, 
THE per monomer. The reaction sequence shown in this equation represents two successive 
mono-oxygenase reaction: NOH-ARG is a tightly bound intermediate and its formation from L- 
arginine requires 1.5 equivalents of NADPH, the successive monooxygenase reaction from 
NOH-ARG to citrulline and NO requires 0.5 equivalents of NADPH. In both steps the four 
electrons necessary to reduce each O2 are derived from both NADPH and the aminoacid 
substrate. In the NOS reaction two molecules of water are coproducts (from Griffith and Stuehr 
1995).
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Mammalian cells are endowed with three genes encoding distinct isoforms of 
NOS. Two NOS are constitutively expressed: endothelial NOS (eNOS) in endothelial 
cells, and neuronal NOS (nNOS) in neurons and various other cell types including 
kidney macula densa cells, B-pancreatic cells, skeletal muscle, and epithelial cells of the 
lung, stomach, and uterus. Synthesis of NO by macrophages is mediated by the third 
species of this enzyme, the inducible NOS (iNOS), not expressed by resting cells and 
induced by a variety of immunological stimuli, as I will extensively describe in a 
following chapter (see chapter 3.9) (Gross et al., 1995). Although all NOS isoforms 
require bound calmodulin for activity, only iNOS has high affinity for calmodulin 
which remains staffly bound, thereby conferring iNOS its full catalytic activity even at 
the low basal calcium concentration of resting cells (Cho et al., 1992). It is thought that 
eNOS and nNOS produce small, physiological concentration of NO in response to 
transient elevation in intracellular calcium, whereas iNOS, when induced, produces 
large and continuous fluxes of NO until substrates become limiting.
In 1991, the cDNA sequence coding for rat cerebellar nNOS was first identified 
(Bredt et al., 1991). The C-terminal portion of nNOS and all subsequently studied NOS 
isoforms show partial homology to NADPH cytochrome P450 reductase, the only other 
mammalian enzyme known to bind both FAD and FMN. Consensus sequences for 
NADPH, FAD, and FMN binding sites were identified within the C-terminal region 
NOS. cDNA and predicted amino acid sequences for eNOS and iNOS have also been 
reported (Fig 8). Regions of high homology are associated with cofactor binding sites. 
In the N-terminal part of the protein lies a region where the three types of NOS share 
65-71% sequence identity. This region contains the putative L-arginine-binding region 
and probably also the binding sites for tetrahydrobiopterin and heme. The binding site
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of calmodulin (CaM) is localized to the central part of the sequence (Griffith et ah,
1995).
Figure 8 Primary sequence map of the three isoforms of human NOS. Comparison 
to human cytochrome P-450 reductase.
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Relationship among the sequences for NOS isoforms and cytochrome P450 reductase. 
Illustrated in the diagram are binding sites for L-arginine, heme, THE, CaM, NADPH, FMN, 
FAD. The grey N-terminal region shows high identity between the three types of NOS. 
Calmodulin is constitutively bound to the iNOS isoform and no Ca2+ is required for binding 
(modified from Griffith and Stuehr 1995).
From a stmcture-function point of view, NOS enzymes are composed of two 
distinct domains that can fold and function also independently of one another: the 
oxygenase (N-terminal) domain, that contains the binding site for heme and substrate.
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and the reductase (C-terminal) domain, with sequence homology to cytochrome P450 
reductase (Sheta et al., 1994; Griffith et al., 1995). Calmodulin-binding region acts as a 
hinge between the C-terminal reductase and the N-terminal oxygenase domains. When 
Ca^Vcalmodulin is not bound, the domains are not aligned, and the reductase domain 
can no longer supply electrons to heme. When Ca^Vcalmodulin is bound, the domains 
align and the enzyme is active (Abu-Soud et al., 1993). This model represents a 
mechanism for nNOS and eNOS activation by increased intracellular [Ca^^] and also 
accounts for the insensitivity of iNOS to changes in [Ca^^ because calmodulin is tightly 
bound to that isoform and does not dissociate. In iNOS, the domains are always aligned, 
and the enzyme is permanently active.
3.8 Evidence for involvement of nitric oxide synthase in immune 
responses
The antimicrobial activity of NO was demonstrated by a variety of approaches. 
Here I will describe the most relevant ones.
3.8.1 Correlation of INOS expression and nitric oxide production with host 
response to infection
Inducible NOS expression is stimulated by microbial products, as well as by 
proinflammatory cytokines produced during immune responses. Infections in humans 
and experimental animals are often associated with significant increases in systemic NO 
production, revealed by measurement of nitrite and nitrate (NO end-products) in plasma 
and urine (Anstey et al., 1996; Evans et al., 1993; Ochoa et al., 1991). Increased iNOS 
expression and NO production can be demonstrated at sites of infection in animal
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models such as toxoplasmosis and leishmaniasis (Stenger et al., 1996), or in human 
infections such as tuberculosis (Nicholson et al., 1996). In cell lines and mice, resistance 
to microbial growth is often associated with expression of iNOS. Replication of 
ectromelia virus, for example, was restricted in IFNy treated NO-producing mouse 
macrophages, yet it was unhindered in fibroblasts or epithelial cells in which IFNy does 
not induce iNOS (Karupiah et al., 1993). Leishmania major was killed more efficiently 
by cytokine-stimulated macrophages from mouse strains resistant rather than 
susceptible to cutaneous leishmaniasis, a distinction reflected in their respective 
expression of iNOS (Liew et al., 1991). Immunohistochemical appearance of iNOS in 
macrophages of resistant C57BL/6 mice was associated with the disappearance of 
Leishmania major from cutaneous lesions and draining lymphonodes (Stenger et al.,
1994).
3.8.2 Decreased host resistance upon treatment with inhibitors of NOS and
disruption of iNOS alleles
More direct evidence for the role of NOSs was obtained after the identification 
of various compounds that inhibit this class of enzymes. These inhibitors were shown to 
worsen the course of diseases caused by a wide array of pathogen: viruses, bacteria, 
fungi, protozoa and helminths (MacMicking et al., 1997).
The pharmacological inhibitors used to block iNOS may also be active to some 
extents on the other NOSs. Moreover, they may have effects unrelated to the inhibition 
of NOS. Therefore, mice deficient in iNOS (iNOS'^") were developed to better clarify 
the function of this enzyme with respect to that of the other gene family members 
(MacMicking et al., 1995; Wei et al., 1995), since such mice completely lack expression
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of iNOS, but not of eNOS and nNOS. Inducible NOS mutant mice are viable, fertile and 
without evident histophatological abnormalities; activation and the respiratory burst of 
macrophages, lymphocytes development, and leucocytes migration are however 
unimpaired. Compared to wild-type and heterozygous mice, iNOS  ^ mice show higher 
sususceptibility to Leishmania major infection (Wei et al., 1995) and their survival is 
reduced upon infection with Listeria monocytogenes (MacMicking et al., 1995). The 
same effect has been observed with various other pathogens. When examined, 
decreased survival correlated with major increases in microbial burden in the affected 
organs (MacMicking et al., 1997). An important issue addressed through the use of 
iNOS  ^ mice is the pathogenesis of septic shock. Excessive NO syntesis within blood 
vessel wall has been implicated as the basis for septic- and cytokine-induced circulatory 
shock, characterized by central blood pressure falls, blood flow maldistribution and 
myocardium depression. Compared to wild-type, inducible NOS mutant mice were 
more resistant to vascular collapse and death induced by EPS (Wei et al., 1995; 
MacMicking et al., 1995).
Immune responses have been investigated also in mice knockout for the other 
NOS isoforms. An involvment of eNOS and nNOS in immune responses has been 
shown in studies with nNOS  ^ and eNOS  ^ mice in two models of colitis, namely 
dextran sodium sulfate- and trinitrobenzene-induced colities (Mashimo et al., 1999). 
The role of NO, or better, the lack of its generation by each constitutive isoform, 
however, is not well defined in these two models. Taken together, these observations 
indicate a major role for NO generated by iNOS in regulating immune responses, 
although also NO generated by constitutive isoforms may play a role in specific 
conditions.
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I will therefore concentrate my analysis on specific aspects of regulation of the 
iNOS enzyme.
3.9 Regulation of inducible nitric oxide synthase
Macrophage iNOS has been isolated as a homodimeric enzyme composed by 
two identical subunits of 130-kDa (Hevel et al., 1991; Stuehr et al., 1991). Subunit 
dimerization is required for activities (Baek et al., 1993). Thus macrophage iNOS 
subunits isolated by gel filtration bind FAD, FMN, and calmodulin but not heme or 
THB and do not generate NO. Subunit dimerization does not occur spontaneously, but 
requires the coincident presence of THB, L-arginine and stoichiometric amounts of 
heme (Baek et al., 1993). Following dimerization, THB and heme, but not L-arginine, 
remain bound. Thus subunit assembly and cofactor binding appear to be a significant 
posttranslational modification leading to active iNOS.
Expression of iNOS in macrophages is induced by cytokines and microbial 
products, primarily at the transcriptional level. Activating cytokines include interferon- 
y (IFNy), interleukin-1 (IL-1) and tumor necrosis factors. Synergism in induction of 
iNOS activity has been observed with the combination of IFNy and any of these agents. 
Cloning and sequencing iNOS gene of the mouse (Lowenstein et al., 1993, Xie et al.,
1993) and human (Chartrain et al., 1994) in the 5'-region upstream of exon 1 has 
revealed the presence of numerous prototypical consensus sequenses for genes that are 
trancriptionally activated by cytokines. The 1749 basepair (bp) upstream flanking 
region of murine iNOS contains more than 20 identifiable putative sequences for 
distinct transcriptional activating factors, including two sites for NF-kB that mediate the 
induction of numerous genes by LPS (Schreck et al., 1992), 10 sites for IFN-y response
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element, 2 sites for IFN-a-stimulated response element, 2 sites for TNF response 
element, and a binding sites for nuclear factor IL-6, and activating protein-1 
(Lowenstein et al., 1993; Xie et al., 1993). Although in iNOS promoter constructs when 
transfected into macrophages in vitro, only a single NF-kB site appears to be necessary 
for activation by LPS (Xie et al., 1993; Xie et al., 1994), induction by LPS was lost or 
diminished in mice knockouts for genes encoding interferon-y (Dalton et al., 1993), a 
subunit of the interferon-y receptor (Huang et al., 1993), or interferon regulatory factor- 
1 (IRF-1) (Kamijo et al., 1994). Thus the IFN-y signalling pathway appears to be crucial 
for induction of iNOS activity in vivo. In addition to enhancing transcription of the 
iNOS promoter, IFN-y may elevate levels of LPS-induced iNOS mRNA via mRNA 
stabilization (Vodovotz et al., 1993). Other stimuli that induce iNOS activity include 
cAMP-elevating agents (Koide et al., 1993) UV-B irradiation (Warren 1994) and 
inhaled ozone (Pendino et al., 1993). Based on the observation that these agents share 
with LPS the capacity to elicit nuclear translocation of NF-kB, the latter factor has been 
proposed as their common mediator (Gross et al., 1995). It is also of interest to note that 
NO itself exerts a biphasic effect on iNOS transcription. Low concentrations, such those 
occurring at the onset of macrophage stimulation by cytokines, activate NF-kB and 
upregulate iNOS (positive feedback) while high concentrations have the opposite effect. 
The latter effect may help preventing NO overproduction (Connelly et al., 2001). 
Moreover, in mesangial cells NO donors can exert stimulatory or inhibitory effects on 
iNOS expression in a time-dependent fashion (Perez-Sala et al., 2001).
Pharmacological levels of glucocorticoids suppress induction of iNOS. Multiple 
mechanisms have been proposed, involving a combination of both transcriptional and 
posttranscriptional effects (Kunz et al., 1996). Interleukin-4 exerted a delayed
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suppressive effect on transcription of iNOS (Bogdan et al., 1994). The most potent 
suppressors known so far in mouse macrophages are however TGFpl to 3 (Vodovotz et 
al., 1994). The physiological importance of this action is shown by the spontaneous 
expression of iNOS in TGF^l-deficient mice (Vodovotz et al., 1996). In vitro studies 
with primary mouse peritoneal macrophages demonstrated that TGFpl destabilizes 
iNOS mRNA, retardes the synthesis of iNOS protein, and accelerates its degradation 
(Vodovotz et al., 1994).
Substrate and cofactor availability are additional important sites for regulation of 
iNOS activity. In most cell types, uptake of L-arginine is mediated by a family of 
cationic amino acid transporter proteins (CATs). In macrophages, CATl and CAT2 are 
upregulated by LPS. After stimulation with IFN-y plus LPS macrophages from CAT2 '^ 
mice showed strong suppression of arginine uptake and NO production. This indicates 
that arginine transporters and iNOS form a functional unit (Closs et al., 2000; Nicholson 
et al., 2001). Extracellular arginine concentration is modulated by arginase, an enzyme 
which degrades arginine to urea and ornithine (Wu et al., 1998). Arginase expression 
appears to be increased in macrophages by various stimuli, among which are TGF-ps 
and LPS (Gotoh et al., 1999; Munder et al., 1999). Upregulation of arginase prior to the 
induction of iNOS prevents NO production by substrate depletion (Munder et al., 1999). 
When both enzymes are coinduced NO production is not impaired (Fligger et al., 1999), 
because the Km value of arginase for arginine is higher than that of iNOS (Wu et al., 
1998; Stuehr 1999). Another level of control of NO generation resides in the ability of 
macrophages to regenerate arginine from citrulline, and thereby to utilize citrulline for 
the production of NO. Argininosuccinate synthetase, the rate limiting enzyme of the 
citrulline-NO cycle, is inducible by LPS in the same cells as iNOS (Nussler et al..
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1994). Heme depletion may account for blockade in macrophages that contain normal 
amouts of iNOS protein (Vodovotz et al., 1994). Another level of post-translational 
iNOS regulation is represented by guanosine triphosphate cyclohydrolase I, the key 
enzyme of BH 4  synthesis. In fact, BH 4  can be rate-limiting to NO synthesis (Wemer- 
Felmayer et al., 2002). Expression of this enzyme can be induced or suppressed by 
cytokines such as IFN-y, TNF, IL-1 and TGF-p.
A final step regulatory mechanism might be phosphorylation since all NOS 
isoforms are phosphorylated within cells (Michel et al., 1997; Stuehr 1999). Although 
serine phosphorylation of eNOS by the Akt kinase is relevant to its activity (Morales- 
Ruiz et al., 2001), the role of phosphorylation of iNOS under physiological condition 
remains still little investigated.
3.10 Mechanisms of action of nitric oxide in the immune responses
3.10.1 Direct antimicrobial action of nitric oxide
Over 50 years ago, nitrites were shown to limit bacterial decomposition of 
meats. The bacteriostatic properties of nitrites were acid-dependent, reflecting the 
formation of nitrous acid (HNO2), which dismutates to NO (MacMicking et al., 1997). 
Numerous bacteria are sensitive to acidified NaN02. Such findings may have relevance 
to the milieu within phagolysosomes of activated macrophages, where low pH could 
help to catalyze the recovery of NO from nitrite, a waste product of NO oxidation, and 
where low pH per se may help restrict microbial growth in conjunction with NO or its 
derivatives (Nathan 1995). A direct action of NO on pathogens has thereafter been 
demonstrated also by experiments with L  major and L. monocytogenes (Liew et al..
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1990; Vincendeau et al., 1991). In these studies treatment with NO-generating 
compounds in the absence of the host cells resulted in inhibition of parasite growth.
Nitric oxide donors can also be toxic to viruses when infecting macrophages. In 
particular, NO donors have rendered host cells virustatic towards diverse taxons, such as 
poxviridae (vaccinia), herpetoviridae (HSV-1 and EBV-1), rhabdoviridae (VSV), and 
retro-viridae (Friend leukemia virus) (MacMicking et al., 1997).
Although significant progress has been made in identifying interactions between 
specific cellular constituents and NO-related species, the critical targets responsible for 
microbial stasis or death by NO are not yet completely clarified. Moreover, significant 
mechanistic differences appear to exist for the various microbial pathogens. For 
example, NO itself does not possess antimicrobial activity for S. typhimurium or 
Escherichia coli (Pacelli et al., 1995; De Groote et al., 1995), but S-nitrosothiols are 
bacteriostatic and peroxynitrite is bactericidal for these organisms. In contrast, S- 
nitrosothiols and NO are microbicidal for Staphyloccoccus aureus (Kaplan et al., 1996) 
and L. major (Assreuy et al., 1994), under conditions in which peroxynitrite does not 
exert any apparent antimicrobial effect.
Reactive nitrogen intermediates have been shown to modify proteins, DNA, and 
also lipids. Nitric oxide interactions with proteins can involve reactive thiols, heme 
groups, iron-sulfur clusters, phenolic or aromatic aminoacid residues, tyrosyl radicals, 
or amines (Fang 1997). Nitrosylation of cysteine residues is one mechanism by which 
NO can directly modify a polypeptide, and NO in theory can reduce the activity of an 
enzyme in case the catalytic site of the latter includes a cysteine residue. Cysteine 
proteases are critical for virulence or replication of many viruses, bacteria, and 
parasites. From this point of view the most sensitive condition is that of many viruses
42
whose genome is translated into a large polyprotein. A viral protease, after excising 
itself from the polyprotein, cleaves the polyprotein into various components, including 
RNA polymerase which then can replicates the viral genome. Viral proteases fall into 
several categories based on their active site residues, including cysteine proteases, 
serine proteases, and aspartic proteases (Babe et al., 1997). While NO does not inhibit 
the replication of some viruses that encode serine proteases, such as alphaviruses, it can 
inhibit the replication of many viruses that encode cysteine proteases, like 
Coxsackievirus (Saura et al., 1999) and members of the Picornavirus family and the 
Coronavirus family (Mannick et al., 1994; Mannick 1995; Reiss et al., 1998). Inhibition 
of Coxsackievirus replication by NO is due, at least in part, to NO nitrosylation of 
cysteine residue in the active site of viral protease (Saura et al., 1999). Nitric oxide 
inactivation of cysteine proteinase could explain the reduction in both viral RNA and 
viral protein levels, given the characteristics of the Coxsackievirus life cycle.
Cysteine proteases are also critical to the replication and virulence of a variety of 
other micro-organisms, such as Plasmodium falciparum, Plasmodium berghei, 
Leishmania major, Schistosima mansoni. Trypanosoma cruzi. Streptococcus pyogenes 
(Bailly et al., 1992; Eakin et al., 1992; Kumar et al., 1994; Selzer et al., 1997; 
Wasilewski et al., 1996; Kapur et al., 1993). As an example, malaria parasite uses its 
cysteine protease falcipain to degrade hemoglobin, to be use as a source of amino acids, 
and cysteine protease inhibitors block the ability of the parasite to infect erythrocytes 
and to replicate (Francis et al., 1994; Dominguez et al., 1997). NO inhibits replicaton 
not only of Plasmodium, but of all the above parasites (MacMicking et al., 1997; Reiss 
et al., 1998). Nitrosylation of cysteine proteases may thus be a general mechanism of
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defence against infections by pathogens whose life cycle depends upon cysteine 
protease activity.
Nitric oxide inhibits the replication also of some viruses that do not encode 
cysteine proteases, implying the existence of other viral targets of NO. For example, in 
the nucleus, NO may regulate EBV reactivation through down-regulation of the 
expression of Zta, the EBV transcription factor that mediates the switch from latent to 
lytic infections (Rooney et al., 1988). Since Zta induces its own expression (Flemington 
et al., 1990), NO may down-regulate Zta expression by inhibiting Zta function. Zta is a 
member of a family that has a cysteine residue within his DNA-binding structure. Under 
oxidizing conditions, the residue forms an intermolecular disulfide bridge between 
dimers which inhibits the ability of these proteins to bind DNA (Bannister et al., 1991). 
Nitric oxide could inhibit Zta function either directly, through S-nitrosylation, or by 
accelerating the formation of a disulfide bond (Stamler 1994; Lipton et al., 1993). Zta 
function can also be inhibited indirectly by NO, since NO activates NF-kB (Lander et 
al., 1993) and NF-kB inhibits Zta induced transcription (Gutsch et al., 1994).
Nitric oxide can interact with iron contained in heme proteins, such as guanylate 
cyclase, which accounts for many of its roles in physiological signal transduction 
(Murad 1994). In contrast to guanylate cyclase which is activated by NO, other heme 
proteins, such as catalase and cytocrome oxidase are inhibited by the gas (Kim et al.,
1995). Several of these enzymes are located within mitochondria and are involved in the 
electron transport chain. Therefore, inhibition of respiration may represent, if prolonged, 
an important cytotoxic action of NO. In aconitase and complexes I, II, as well as 
cytochrome c oxidase of the respiratory chain NO has been shown to react with the 
iron-sulphur clusters. The end result of such actions is ATP depletion of target cells and
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hence cytotoxicity. Nitric oxide can also inactivate phosphoenolpyruvate carboxykinase 
and glyceraldehyde-3-phosphate dehydrogenase, both of which are important in glucose 
metabolism, and thereby reduce the energy production of target cells (Ou et al., 1996).
Several lines of evidence indicate that DNA is an important target of reactive 
nitrogen intermediates. Some of the effects of NO on DNA may involve imparment of 
DNA synthesis as well as direct modifications of deoxyribonucleotides. Nitric oxide has 
an inhibitory effect on vaccinia virus growth through a specific inhibition of the activity 
of ribonucleotide reductase, which is DNA-synthesizing enzymes (Melkova et al.,
1995). Both in vitro and in intact bacteria NO can deaminate DNA, acting via an N- 
nitrosating intermediate (Routledge et al., 1993; Maragos et al., 1993). NO2 and 
peroxynitrite can also oxidatively damage DNA, resulting in abasic sites, strand breaks, 
and a variety of other DNA alterations (Maragos et al., 1993).
Nitric oxide has been shown to induce membrane damage, an action mainly 
sustained by formation of peroxynitrite. Peroxynitrite has been found to mediated lipid 
peroxidation via a mechanism which does not require iron (Rubbo et al., 1994). Also 
NO2 can induce lipid peroxidation (Halliwell et al., 1992). The relationship between 
these actions and NO-related antimicrobial activity is unknown.
3.10.2 Indirect antimicrobial action of nitric oxide through modulation of immune 
cells function
3.10.2.1 Nitric oxide modulates mast cell functions
Nitric oxide is not only a direct toxic agent towards infectious organisms, but 
exerts its function through regulatory effects on many cells types involved in immune 
responses. Mast cells are highly specialized secretory cells that play important roles in
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IgE-mediated allergy and inflammation. After exposure to allergenes mast cells release 
by exocytosis histamine, heparin and proteases, stored in their dense granules. Inhibition 
of NO on anti-IgE- and Ca^^ ionophore-induced histamine release has been 
demonstrated in rat and human mast cells (Jorens et al., 1993; likura et al., 1998). lEN-y 
show similar effects, in fact it inhibits IgE/antigen-induced degranulation and mediator 
release from mouse and rat mast cells. This action of the cytokine is however indirect 
since it is far stonger in mixed peritoneal cells compared to purified mast cells 
preparations. The active intermediate has been shown to be NO (Eastmond et al., 1997). 
Additionally, mast cells are a rich source of diverse cytokines that are synthesized de 
novo upon cell activation or, as in the case of TNF-a, are stored ‘ready-to-go’ in the 
secretory granules. In a rat cell line model a panel of NO donors induced a time- 
dependent, and in some case reversible, inhibition of IgE/antigen-induced expression of 
mRNA for TNF-a, IL-4 and IL-6 (Coleman 2002). Nitric oxide inhibits mast cells 
degranulation only after prolonged incubation times (up to 24 h) before antigen 
challenge. This ‘slow’ responsiveness of cultured as well as of primary mast cells is 
consistent with sustained NO generation by iNOS rather than with transient NO 
generation by constitutive NOS (Eastmond et al., 1997; Deschoolmeester et al., 1999). 
Several in vivo models demonstrate that NO inhibits various mast cell-dependent 
processes including histamine-mediated vasodilatation, leucocyte adhesion to the 
vascular endothelium and epithelial permeability, all of them involved in the 
inflammatory responses induced by these cells (Kanwar et al., 1994; Kimura et al.,
1999).
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3.10.2.2 Nitric oxide role in neutrophil activation
Neutrophils are relevant to the non-specific immune response to bacterial 
infection. The neutrophil action is characterised by adhesion to the vascular 
endothelium followed by migration into tissues, oxygen radical-dependent killing of 
microbes and their elimination, together with damaged tissue debris, by phagocytosis. 
Since the agents released by activated neutrophils are potentially toxic to host tissues, 
neutrophils are subsequently eliminated by apoptosis and engulfment by macrophages. 
Thus, modulation of the activation status of neutrophils is of key importance in 
determining the balance between immune defense and host injury (Armstrong 2001). 
Human blood neutrophils, stimulated in vitro with monocytes-derived cytokines, and 
neutrophils from inflamed exudates are reported to express iNOS (Evans et al., 1996; 
Armstrong 2001). In spite of these reports, there is still controversy as to whether 
human neutrophils can produce functionally significant levels of NO. For example. 
Miles et al. (Miles et al., 1995) reported that rat peritoneal neutrophils express iNOS, 
whereas circulating and extravasated human neutrophils, derived from peritoneal 
dialysis of peritonitis patients, did not express iNOS mRNA, iNOS protein and 
enzymatic activity. Rat neutrophils express the constitutive neuronal type NOS RNA 
and protein. Accordingly, these cells generate basal levels of nitrate/nitrite. Human 
neutrophils, on the other hand, also express nNOS mRNA, however the nNOS enzyme 
and NO production were not detected (Greenberg et al., 1998). Overall, it appears that 
there are differences between human and rodent neutrophils in terms of NO production 
and, possibly also in the NOS isoforms involved. There is considerable evidence, 
however, that NO and cyclic GMP act as endogenous mediators of the chemotactic 
response of neutrophils. NOS inhibitors, in fact, reduced neutrophil chemotaxis induced
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by the bacterial peptide n-formyl-methionyl-leucyl-phenylalanine (fMLP) (Wanikiat et 
ah, 1997; Belenky et ah, 1993). The role of iNOS-derived NO in neutrophil migration 
has also been examined in gene knockout studies and differences in kinetics were 
observed between the two types of mice (Ajuebor et al., 1998). Despite results from 
studies with NOS inhibitors indicating that endogenous NO acts as a mediator of 
neutrophil chemotaxis, paradoxically NO donors inhibit various aspects of neutrophil 
activation, including chemotaxis (Wanikiat et al., 1997). An explanation for these 
contradictory findings has been proposed by R. Armstrong (Armstrong 2001): NO 
effects are concentration-dependent, whereby low concentrations stimulate chemotaxis 
and high concentrations are inhibitory. Thus, the high increase in NO and cyclic GMP 
observed concomitant with neutrophil activation might represent a negative feedback 
pathway.
Phagocytosis is a relevant function of neutrophils, however evidence for a role 
of NO in this process is still limited. An early study suggested that endogenous NO 
could play a role in human neutrophil phagocytosis since anucleate neutrophil 
cytoplasts decreased their uptake and killing of staphylococci in the presence of the 
NOS inhibitor L-NMMA, an effect that was reversed by L-arginine (Malawista et al., 
1992). Subsequently, L-arginine supplementation was shown to increase phagocytosis 
of staphilococcus by human neutrophils (Moffat et al., 1996). In contrast to these 
findings, the NO donor GEA 5171 has been shown to inhibit rather than stimulate 
neutrophil phagocytosis (Forslund et al., 1997). However, no studies with other NO 
donors have been carried out yet.
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3.10.2.3 Natural killer cells and Nitric oxide
Natural killer (NK) cells, a major component of innate immunity, play an 
important role in host resistance to infections from bacteria, viruses and parasites (Biron 
1997; Scharton-Kersten et ah, 1997). In addition, NK cells are involved in immune 
surveillance of tumors and rejection of transplanted organs (Whiteside et al., 1995; 
Lanier 1995) and they can also influence the adaptive immune system and direct the 
pattern of T responses (Kos 1998). The functions of NK cells, as well as their 
maturation and differentiation, are regulated by various stimuli, including IL-2, IL-12, 
IL-15, and IL-18. In particular, unlike most T lymphocytes, resting NK cells express 
functional IL-2 receptor Py (IL-2RPy) and respond to IL-2 without prior stimulation. 
Once activated by IL-2, NK cells acquired enhanced cytotoxic function (known as 
lymphokine-activated killing, LAK) recognizing a broader range of targets and killing 
with increased lytic potential (Cifone et al., 2001).
Natural killer cells employ cytolysis and cytokine production as major effector 
mechanisms. The final outcome of their activity results from a balance between 
activation of stimulatory and inhibitory receptors and ligands. Natural killer cells 
express a number of inhibitory receptors that recognize MHC class I molecules 
expressed on normal cells (Cifone et al., 2001). Insufficient expression of class I 
molecules, or lack of expression of one or more class I alleles render target cells more 
prone to NK-mediated lysis, as originally proposed by Ljunggren and Karre (Ljunggren 
et al., 1990) in the “missing-self hypothesis”. Thus, cells that lack class I molecules as a 
consequence of infection or mutations are sensitive to cytolysis by NK cells. Some 
tumor cells expressing high levels of autologous class I molecules are nevertheless 
sensitive to cytolysis by NK cells, indicating that these molecules are not the only
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mechanism of target cell discrimination by NK cells (Moretta et al., 1996). Many 
receptors responsible for NK cell triggering in the process of natural cytotoxicity 
(natural cytotoxicity receptors, NCR) have been characterized (Moretta et al., 2000). 
Upon cross-linking, NCR mediate NK cell triggering, leading to target cell lysis and 
cytokine production. The function of NCR is normally downregulated by co­
aggregation with killer inhibitory receptors. Thus, induction of NK cell activation via 
NCR occurs in the absence of a killer inhibitory receptor-HLA class I interaction 
(Cifone et al., 2001).
Natural killer-mediated cytotoxicity is directly dependent upon concentration of 
L-arginine in the culture medium (Cifone et al., 1994) and L-NMMA, a non-specific 
inhibitor of NOS, abolishes, in a dose dependent fashion, the cytotoxic activity of NK 
cells (Reif et al., 1995). This evidence supports a role for NO in the lytic events 
mediated by NK. Nitric oxide is also an effector molecule that mediate, at least 
partially, the tumoricidal effects of rat IL-2-activated NK cells, as it occurred with fresh 
NK cells (Yim et al., 1995; Jyothi et al., 1999). On the other hand, increasing levels of 
NOS activity were observed during LAK generation, a process found to be arginine- 
dependent (Cifone et al., 1994). The role of NO in LAK generation has been confirmed 
by Juretic et al. (Juretic et al., 1994), who reported that L-NMMA is inhibitory in the 
mouse. In human LAK cells, however, no dependence on NO could be demonstrated, 
suggesting a different regulation of the NO pathway in the two species. The analysis of 
iNOS expression at mRNA and protein levels in IL-2-treated NK cells established that 
NO generation is due to the induction of iNOS, rather then eNOS or nNOS (Cifone et 
al., 1999). Consistent with these findings, mice genetically lacking iNOS have impaired 
NK cell killing of YAC-1 target cells (Diefenbach et al., 1998). Nitric oxide affects NK
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cells expression and production of cytokines such as IFN-y or TGF-p (Bogdan et al.,
2000). The activation of iNOS/NO is necessary for the activation of Tyk2 kinase and 
thus for IL-12 and IFN-a/p signalling in NK cells (Diefenbach et al., 1999).
3.10.2.4 Nitric oxide and T cell immunity
In rodent mixed lymphocyte cultures and in vivo models of T cell-mediated 
immunity macrophage-derived NO was first shown to inhibit T lymphocyte 
proliferation (Langrehr et al., 1993; van der Veen 2001). Subsequent studies in mice 
suggested that NO, preferentially produced by the Thl subset of T helper lymphocytes 
(Taylor-Robinson et al., 1994), inhibits selectively Thl responses and the production of 
the Thl cytokine, IFN-y (Wei et al., 1995). These findings led to the speculation that 
Thl cell-derived NO could down-regulate Thl cell responses in an autocrine manner, 
and at the same time promote Th2 responses, possibly leading to enhanced production 
of IgE and promotion of IgE-mediated diseases such as asthma (Barnes et al., 1995). 
However, these findings and conclusions have since been questioned (van der Veen 
2001; Thuring et al., 1995; van der Veen et al., 1999; Bauer et al., 1997). For example, 
Thuring et al. (Thuring et al., 1995) found no evidence of NO production by mouse 
lymphocytes or T cell clones. Likewise, van der Veen et al. (van der Veen et al., 1999; 
van der Veen 2001) found that mouse Thl cells do not express NOS-2 and also that NO 
inhibits equally well the proliferation of both mouse Thl and Th2 cells, without 
inhibiting production of IFN-y and other cytokines. Another study found that NO 
inhibits production of both Thl and Th2 cytokines by human T lymphocytes (Bauer et 
al., 1997).
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There is evidence that NO has different effects on Thl differentiation depending 
on its concentration. Indeed, Thl cells produce IFN-y which activates macrophages to 
express high levels of iNOS, and produce large amounts of NO that inhibit the 
expansion of Thl cells by a feedback mechanism (Huang et al., 1998). Low 
concentrations of NO, on the other hand, have a selective enhancing effect on the 
induction and differentiation of Thl, but not Th2 cells. This bi-phasic function of NO in 
immune regulation may be important for the fine tuning of the immune system 
(Niedbala et al., 1999).
Because of its capacity to induce apoptosis (Brune et al., 1999), NO might play a 
role as effector molecule in the selection and development of T cells in the thymus. In 
mouse, rat or human thymocytes, iNOS protein is absent (Tai et al., 1997; Aiello et al., 
2000; Moulian et al., 2001). In the murine thymus, however, very few iNOS^ cells were 
detected in unstimulated animals, and a major increase in the number of iNOS^ cells 
was observed in both fetal and adult thymuses after stimulation with an anti-CD3 
antibody (Tai et al., 1997). In the human thymus, on the other hand, iNOS^ cells are 
present in the cortex, in the medulla and around the vessels, and some of them are 
epithelial. Consistent with this result cultured thymic epithelial cells produce iNOS 
when activated by IFN-y, TNFa and ILip, 3 cytokines potentially produced by the 
thymic microenvironment (Moulian et al., 2001). TCR-activated double-positive 
thymocytes are highly sensitive to the killing by NO (in particular by peroxynitrite), 
whereas single-positive thymocytes remain viable upon exposure to NO (Tai et al., 
1997; Aiello et al., 2000; Moulian et al., 2001; Fehsel et al., 1995; Brito et al., 1999). 
These data suggest that NO released by iNOS-positive thymic stromal cells is one of the
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factors mediating deletion of double-positive thymocytes. The function of eNOS 
expression in thymocytes is still unknown (Cruz et al., 1998).
3.10.2.5 Nitric oxide and dendritic cells: a fascinating story still at its 
beginning.
Macrophages, which may share a common ontogeny with DCs, respond to stress 
(such as LPS or inflammatory cytokines) with the generation of NO (Stuehr et al., 
1987). Such a response was never reported in DCs stimulated by cytokine or LPS until 
1996, when Thomson described the production of NO by highly purified DEC 205* 
DCs propagated from mouse bone marrow by granulocyte/macrophage-colony 
stimulating factor (GM-CSF) plus interleukin-4 (IL-4). Nitric oxide synthesis was found 
to be induced in DCs by IFN- y and LPS, and blocked by the NOS inhibitor N^-mono- 
methyl-L-arginine (NMMA) (Bonham et al., 1996). Induction of iNOS mRNA was 
demonstrated in purified murine DCs stimulated with LPS and IFN-y, and the 
intracellular protein product was visualized by two-color flow cytometry. Of particular 
interest was the observation that only a subpopulation of highly purified IFN-y 
plus LPS-stimulated DCs express iNOS. Nitric oxide was also detected in the 
supernatants of primary mixed leukocytes cultures containing high concentrations of 
DCs with respect to purified allogeneic T cells. Furthermore, inhibition of NO release in 
these cultures by NMMA resulted in an increase in T cell proliferation. These 
observations suggest that NO may be an important soluble mediator of the interaction 
between DCs and activated T cells.
T lymphocytes, moreover, can play key roles in the regulation of NOS 
expression since CD40 ligation by mAb does induce NO production by murine DCs. In
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addition to its ability to inhibit T cell proliferation, NO was also shown to induce 
programmed cell death in DCs (Lu et al., 1996; Bonham et al., 1996). Experiments in 
rodents show in fact that generation of NO by iNOS-expressing thymic DCs contributes 
to the clonal deletion of thymocytes (Aiello et al., 2000). Spontaneous remission of 
experimental allergic encephalomyelitis (EAE), a mouse model for multiple sclerosis, is 
usually associated with prominent apoptosis. Recovery from EAE is associated with 
functional changes in DC functions, including elevated proliferation, increased IFN-y 
secretion and NO production. Since DCs-derived NO results in apoptosis of 
autoreactive CD4* T cells, thereby inhibiting autoreactive T cell responses, such a NO 
negative feedback loop may contribute to remission of EAE (Downing et al., 1998; 
Xiao et al., 1999).
So far, regulation by NO of human DC function has been poorly investigated. At 
variance with rodents, iNOS expression and NO production by human-derived DCs 
have not been reported, except in defined pathological condition, namely primary 
biliary cirrhosis, chronic hepatitis B and hepatocellular carcinoma. Dendritic cells from 
patients affected by these diseases produce NO, and their high endocytic ability reveales 
an immature phenotype, suggestive of a defective maturation programme (Wang et al., 
2001; Yamamoto et al., 1998; Ninomiya et al., 1999). Dendritic cells from these patients 
express significantly lower levels of costimulatory molecules and HLA DR; furthermore 
their T cell stimulatory activity is lower than in normal DCs.
I can conclude that the existence of a role of NO in regulating the function of 
human DCs, although supported by extensive information, appears still poorly 
understood. The scope of my thesis’ work has been to initiate the filling of this gap.
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4 AIMS OF THE WORK
The goal of this thesis was to evaluate if NO can indeed influence human DC functions 
when the latter cells are exposed to maturation stimuli, and to establish the molecular 
mechanisms of this NO action.
Specific aims were:
1. To establish whether NO can modulate DC endocytosis of soluble antigens.
2. To establish whether exposure of DCs to NO does influence their ability to 
induce T lymphocyte activation.
3. To establish whether NO does influence expression of membrane molecules that 
are upregulated during DC maturation.
4. To identify DC-produced factors modulated by NO which are involved in T cells 
activation.
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5 RESULTS
5.1 Nitric oxde reverses the inhibition of endocytosis induced by 
tumour necrosis factor-a in dendritic cells
5.1.1 Nitric oxide modulates endocytosis in dendritic cells undergoing TNF-a- 
induced maturation
Human monocyte-derived DCs retain their ability to uptake antigens. This 
ability is progressively lost when DCs are treated with TNF-a (Sallusto et al., 1994). I 
have investigated the role of NO in the modulation of the endocytic activity of DCs 
using the well characterized fluorochrome-labelled FITC-dextran, as a marker of 
endocytosis. Two different sources of the gaseous messenger were used: the NO donors 
DETA-NO and SNAP; and the N9 murine microglial cells activated with polystirene 
microspheres and IFN-y, a treatment which induces expression of iNOS and continuous 
generation of bioactive NO (Sciorati et al., 1999; Corradin et al., 1993). In the first 
experimental approach, immature DCs were incubated in a double chamber system with 
or without TNF-a (200 ng/ml, 48 h), in the presence or absence of activated N9 cells. 
Dendritic cells were then resuspended in cytokine-free medium and incubated with 
FITC-dextran, and internalisation of the latter measured by flow cytometry. In the 
untreated,, immature DCs incubated at 37°C, uptake of FITC-dextran was found to 
proceed linearly for 15 min and then to progressively level off. In contrast, at 4°C no 
uptake was detected (Fig. 9). In DCs pretreated with TNF-a for 48 h significantly 
decreased endocytosis of FITC-dextran was found at all time-points of the experiment, 
i.e. up to 1 h (Fig. 9).
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Figure 9 Effects of NO generated by iNOS-expressing N9 cells on the endocytic
activity of DCs treated with TNF-a
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Immature DCs were cultured without TNF-a (H ), with TNF-a (0 ) ,  or with TNF-a and iNOS- 
expressing N9 cells (A) for 48 h. Cells were then washed, suspended in fresh culture medium 
with or without FITC-dextran (1 mg/ml) and endocytosis at 37°C analysed at the indicated time- 
points as described in the Methods. As a control, endocytosis of FITC-dextran was measured 
also at 4°C in cells which were not exposed to TNF-a (♦  ). Endocytosis was calculated as % of 
cells positive to FITC-dextran (DX) with respect to cells treated in the same way but not 
exposed to the fluorescent dye. Statistical probability vs cells treated with TNF-a alone is 
indicated by the marks * and calculated as described in the Methods (n = 5).
57
This effect of TNF-a was not due to cytotoxicity since cell viability was 94 ± 
3.8 % after the 48 h pretreatment with the cytokine (n = 5). When the preincubation 
with TNF-a was carried out in the presence of activated N9 cells the inhibition of 
endocytosis was largely prevented at all time-points investigated (Fig. 9). This effect 
was suppressed when incubation of DCs with activated N9 cells was carried out in the 
presence of the NOS inhibitors aminoguanidine (1 mM) or L-NAME (1 mM) (Fig. 10). 
Moreover, the effect of the inhibitors was proportional to their ability to reduce NO 
release by the N9 cells, measured as nitrite accumulation in the culture medium (Fig. 
10, lower panel).
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Figure 10 NOS inhibitors abolish the effect of N9 cells on endocytosis activity of
DCs treated with TNF-a
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Immature DCs were incubated for 48 h with or without TNF-oc (200 ng/ml), in the presence or 
absence of iNOS expressing N9 cells, the NOS inhibitors aminoguanidine (AG, 1 mM) and L- 
NAME (1 mM), as indicated in the key. The incubation medium was removed and the nitrite 
concentration in it measured as described in the Methods. Cells were resuspended in fresh 
culture medium with or without FITC-dextran for 30 min. Endocytosis was calculated as 
described in A and values expressed as % of those measured in cells incubated without TNF-a 
(100 %). In both panels statistical probability vs cells treated with TNF-a alone is indicated by 
the marks * and calculated as described in the Methods. The marks 4-  in panel B refer to the 
statistical probability vs DCs treated with TNF-a in the presence of N9 cells {n -  5).
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In the second experimental approach, immature DCs were incubated for 48 h 
with TNF-a (0.2-200 ng/ml) in the presence or absence of either DETA-NO (100 pM) 
or SNAP (200 pM). Diethylenetriamine-nitric oxide adduct (DETA/NO) is a long- 
acting nucleophile molecule developed for the controlled release of NO (Wink DA and 
Kasprzak KS, 1991, Science). At the concentration used, this NO donor releases a 
constant flux of 50 ± 2.3 nM NO {n = 4), as measured by a NO electrode (Clementi et 
al., 1998). Also in this experiment TNF-a induced a concentration-dependent inhibition 
of endocytosis (Fig. 11 A) which was largely prevented by either NO donor (Fig 11, A 
and B). Decomposed DETA-NO and SNAP, which are unable to release NO as 
measured by a NO-sensitive electrode, did not have any significant effect on the TNF-a 
inhibition of endocytosis (Fig. 11 B). Moreover, NO donors or activated N9 cells failed 
to induce any significant effect on endocytosis of DCs not pretreated with TNF-a (not 
shown). Moreover, NO donors did not induce cytotoxicity (viability vs untreated 
controls was 95 ± 5.0 % and 93 ± 4.3 % after the 48 h incubation with DETA-NO and 
SNAP, respectively, n = 3).
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Figure 11 Effects of NO generated by NO donors on the endocytic activity of DCs
treated with TNF-a
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A: Immature DCs were incubated for 48 h with or without TNF-a (0.2-200 ng/ml) in the 
presence (triangles) or absence (circles) of DETA-NO (100 |tM), washed and resuspended in 
fresh culture medium with or without FITC-dextran.
B: Immature DCs were incubated for 48 h with or without TNF-a (200 ng/ml) in the presence or 
absence of DETA-NO (100 pM) or SNAP (200 pM) either able or unable to release NO 
(decayed compounds) as indicated in the key. In both panels endocytosis was calculated as in 
Fig. 5 after 30 min incubation with or without FITC-dextran. Statistical probability vs cells 
treated with TNF-a alone is indicated by the marks * and calculated as described in the Methods 
{n = 5).
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5.1.2 The effect of nitric oxide on endocytosis of dendritic cells undergoing TNF-
a-induced maturation is cGMP-dependent
Nitric oxide biological effects are mediated through signalling pathways both 
dependent and independent of the gas ability to activate guanylate cyclase and generate 
cGMP (Moncada et ah, 1995). Thus I investigated if NO donors could activate 
guanylate cyclase and increase cGMP generation in immature DCs with respect to 
untreated controls. In the present experimental setting administration of DETA-NO 
induced generation of cGMP, which was inhibited in a concentration-dependent way by 
ODQ, a specific guanylate cyclase inhibitor (Garthwaite et al., 1995) (Fig 12A). The 
dependence on cGMP of the effects of NO on endocytosis was then investigated. 
Immature DCs were treated with TNF-a (48 h) in the presence or absence of NO 
donors, either alone or in the presence of ODQ, or of the membrane-permeant cGMP 
analogue 8-Br-cGMP (3 mM). As shown in Fig. 12 B, DETA-NO and SNAP prevented 
the effect of TNF-a on endocytosis of FITC-dextran. This action of the NO donors was 
inhibited by ODQ and mimicked by 8-Br-cGMP. These results indicate that NO 
controls endocytosis regulated by TNF-a through the activation of cGMP-dependent 
pathway(s).
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Figure 12 Effects of cGMP on the endocytic activity of DCs treated with TNF-a
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A: Immature DCs were pre-treated for 15 min with the phosphodiesterase inhibitor 3-isobutyl-1- 
methyl xanthine (0.5 mM), and then incubated for 30 min with increasing concentrations of 
ODQ (0-5 pM) in the presence or absence of DETA-NO (100 pM). cGMP generation in the 
various experimental conditions was measured using a radioimmunoassay specific for the cyclic 
nucleotide.
B: Immature DCs were incubated for 48 h with or without TNF-oc (200 ng/ml), in the presence 
or absence of DETA-NO (100 pM), SNAP (200 pM), the membrane permeant cGMP analogue 
8 -Br-cGMP (3 mM), or the inhibitor of soluble guanylyl cyclase ODQ (3 pM) as indicated in 
the key. Endocytosis was measured after 30 min of incubation with or without FITC-dextran and 
calculated as in Fig. 10. Statistical probability vs cells treated with TNF-a alone is indicated by 
the marks * and calculated as described in the Methods. The marks + refer to the statistical 
probability in cells treated with TNF-a, ODQ and either NO donor vs cells treated without ODQ 
(n = 3).
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5.7.3 Accumulation of ceramide induced by TNF-a in dendritic cells is inhibited
by nitric oxide in a cGMP-dependent fashion.
Ceramide, a second messenger generated by the activation of the p55 receptor of 
TNF-a, has been shown to mediate some of the effects of the cytokine in DCs (Sallusto 
et ah, 1996). The time-course of ceramide accumulation by DCs treated with TNF-a is 
shown in Figure 13 A. The cytokine induced a progressive accumulation of the lipid 
messenger, which reached a plateau after about 6 h and remained constant thereafter. 
No significant ceramide accumulation was observed in cells not exposed to TNF-a (Fig. 
13 A). When DCs were incubated with the cytokine in the presence of activated N9 
cells, ceramide accumulation was reduced and a negative correlation was found between 
the amount of NO generated, measured as the concentration of nitrite released in the 
medium, and the intracellular accumulation of ceramide (Fig. 13 B).
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Figure 13 Effects of NO and cGMP on the TNF-a-induced ceramide accumulation
in DCs
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A: immature DCs were treated with ( • )  or without (♦) TNF-a (200 ng/ml). Cell aliquots were 
collected at the indicated time-points, lysed and ceramide content measured by thin layer 
chromatography as described in the Methods. Statistical probability vs cells treated without 
TNF-a is indicated by the marks * and calculated as described in the Methods.
B: immature DCs were treated with TNF-a (200 ng/ml) and iNOS expressing N9 cells (■) for 
the indicated time-points. Ceramide accumulation was measured as in A. Values are expressed 
as % of those measured in DCs treated with TNF-a in the absence of N9 cells (control). The 
bars show the nitrite concentration in the medium measured as described in the Methods. 
Statistical probability vs cells treated with TNF-a alone is indicated by the marks * and 
calculated as described in the Methods (n = 4).
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A similar inhibition of ceramide accumulation induced by TN F-a was observed in cells 
incubated with DETA-NO or SNAP (Fig. 14). Also this effect of NO appeared to be 
cGMP-dependent inasmuch as it was prevented by incubation with the NO donors in the 
presence of ODQ and was mimicked by 8 -Br-cGMP.
Figure 14 The effects of NO on the TNF-a-induced ceramide accumulation in DCs 
are cGMP dependent.
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Cells were treated for 6  h with TNF-a with or without DETA-NO (100 pM), SNAP (200 pM), 
8  Br-cGMP (3 mM) and ODQ (3 pM) as indicated in the key. Values are expressed as % of 
those measured in DCs treated with TNF-a. Statistical probability vs cells treated with TNF-a 
alone is indicated by the marks * and calculated as described in the Methods. The marks 4- refer 
to the statistical probability in cells treated with TNF-a, ODQ and either NO donor vs cells 
treated without ODQ (n = 4).
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5.1.4 The nitric oxide/cGMP action on dendritic cells endocytosis is exerted both
upstream and downstream of the TNF-a-induced generation of ceramide.
Long-term incubation of DCs with exogenous C2 ceramide (80 pM, 48 h)
resulted in a statistically significant, persistent inhibition of FITC-dextran endocytosis 
with respect to that observed in untreated, control cells (Fig. 15 A). When DC 
incubation with exogenous C2 ceramide was carried out in the presence of DFTA-NO 
(Fig. 10, A and B) or SNAP (Fig. 15 B), the inhibition of endocytosis by the lipid 
metabolite was reduced. This effect of the NO donors was prevented by incubation with 
ODQ and mimicked by 8-Br-cGMP (Fig. 15 B). These results indicate that the action of 
NO is exerted not only via the inhibition of the TNF-a-induced ceramide generation, 
but also via (a) mechanism(s) active downstream of the latter process. Both these effects 
of NO appear dependent on cGMP generation.
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Figure 15 Effects of NO on the endocytic activity of DCs treated with ceramide
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A: immature DCs were incubated without C2  ceramide (■), with C2 ~ceramide (80 jiM; ^  ), or
with C2 -ceramide and the NO donor DETA-NO (100 |aM; • )  for 48 h. Cells were then washed,
suspended in fresh culture medium with or without FITC-dextran (1 mg/ml) and endocytosis at 
37°C analysed at the indicated time-points as described in the Methods. As a control, 
endocytosis of FITC-dextran was measured also at 4°C in cells which were not exposed to C2
ceramide ( ^  ). Endocytosis was calculated as described in Fig 4.
B: immature DCs were incubated with or without C2 -ceramide as in A, in the presence or 
absence of DETA-NO (100 pM), SNAP (200 pM), ODQ (3 pM), or 8  Br-cGMP (3 mM) as 
indicated in the key. Endocytosis was measured after 30 min of incubation with or without 
FITC-dextran, calculated as described in A and values expressed as % of those measured in cells 
incubated without C2 -ceramide (100 %). In both panels statistical probability vs cells treated 
with C2 "Ceramide alone is indicated by the marks * and calculated as described in the Methods. 
The marks -t- in panel B refer to the statistical probability in cells treated with C2 -ceramide, 
ODQ and either NO donor vs cells treated without ODQ (n = 4).
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5.1.5 Treatment with cytokines and LPS does not induce generation of nitric 
oxide by dendritic cells.
Expression of iNOS and generation of NO by DCs has been reported in rodents 
both in vivo (Downing et ah, 1998) and in purified DCs after treatment with IFN-y and 
LPS in vitro (Lu et al., 1996; Xiao et al., 1999). I therefore investigated whether 
exposure of human-derived DCs to cytokines and LPS also induces expression of iNOS 
and generation of NO. Immature DCs were incubated for 48 h in the presence or 
absence of human TNF-a, human IFN-y (100 U/ml) and LPS (10 pg/ml), alone or 
combined as detailed in Fig. 16. NO generation was measured in the culture medium as 
nitrite formation, and the expression of iNOS analysed by Western blotting of DC 
lysates. Neither iNOS expression in DCs nor nitrite accumulation in the medium were 
detected before or after any of the treatments applied (Fig. 16 and not shown). It is 
possible to conclude that DCs are unable to modulate their endocytosis decrease process 
by endogenous generation of NO.
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Figure 16 Effects of cytokines and LPS on iNOS expression in DCs
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Effects of cytokines and LPS on iNOS expression in DCs. Immature DCs were treated for 48 
h in the absence or presence of: TNF-a (200 ng/ml, 2 and 3, respectively); TNF-a, IFN-y (100 
U/ml) and LPS (10 pg/ml, 4); IFN-y and LPS (5). Cells were lysed and iNOS expression 
revealed by Western blotting with an anti iNOS Ab as described in the Methods. As a positive 
control, N9 cells, activated as described in the Methods, were loaded in parallel (1). The results 
shown are from one experiment representative of four consistent ones.
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5.2 Synergism between nitric oxide and maturation signals in 
dendritic cells leads to an enhancement of T lymphocyte 
activation.
5.2.1 T lymphocyte activation by TNF-a-treated dendritic cells is enhanced by 
nitric oxide.
Immature DCs were treated for 2 days with or without TNF-a (50 ng/ml) in the 
presence or absence of the NO donor DETA-NO (50 pM), then washed free of the 
cytokine and the NO donor. As previously reported, this NO donor releases a constant 
flux of NO and does not affect DC viability. The antigen presenting function of 
pretreated DCs was evaluated by measuring DC-induced proliferation of either 
allogeneic T lymphocytes in MLRs (Fig. 17 A), or autologous T lymphocytes 
stimulated with SEE (0.2 pg/ml), PPD (1 pg/ml) or anti-CD3 mAh (0.1 pg/10^ cells) 
(Fig. 17 B). In all these experimental settings, pre-treatment with DETA-NO alone 
resulted in no changes in DC-induced T cell proliferation. By contrast, when the NO 
donor was administered to DCs together with TNF-a, stimulation of T cells was 
increased. T cell proliferation was significantly higher than that induced by either 
untreated DCs or DCs pre-treated with TNF-a alone, both in MLRs (Fig. 17 A) and 
when autologous reactions in the presence of SEE, anti-CD3 mAh or PPD (Fig. 17 B). 
Regardless of the pre-treatment, DCs alone induced no significant proliferation of 
unstimulated, autologous T cells (Fig. 17 B).
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Figure 17 NO enhances the ability of TNF-a-treated DCs to induce T cell
activation
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Immature DCs were treated for 2 days with or without TNF-a (50 ng/ml) in the presence or 
absence of DETA-NO (50 pM). A: These pre-treated DCs were co-cultured at the indicated 
ratios with a fixed number of allogeneic T cells (10^ cells/well); proliferation (^H-thymidine 
incorporation in T cells) was measured after 3 and 5 days of DC/T cell co-culture. B: 2x10^ pre­
treated DCs were co-cultured with 10^  autologous T cells in the presence of SEE (0.2 pg/ml), 
anti-CD3 (0.1 pg/10^ cells), PPD (1 pg/ml) or without any stimulus. Proliferation was measured 
after 3 days. Asterisks indicate statistical significance, measured as indicated in Materials and 
methods, of TNE-o/DETA-NO DCs vs. TNE-a-treated DCs (n = 8 ).
72
The concentration of IFN-y and IL-2 accumulated in the medium under the 
various experimental conditions described above was measured. Figure 18 shows the 
results obtained using SEB-stimulated T cells. IFN-y and IL-2 released in the presence 
of DCs pre-treated with DETA-NO alone were similar to those released with immature, 
untreated DCs. Pre-treatment of DCs with TNF-a resulted in increased release of both 
cytokines, which was further, significantly enhanced in the presence of the NO donor. 
In the absence of SEE no significant release of IFN-y and IL-2 was observed, regardless 
on whether lymphocytes were cultured alone or in the presence of untreated, immature 
DCs.
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Figure 18 NO enhances the ability of TNF-a-treated DCs to induce IFNy and IL-2
production by T cells.
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Immature DCs were treated for 2 days with or without TNF-a (50 ng/ml) in the presence or 
absence of DETA-NO (50 pM). IFN-y and IL-2 secretion were measured in the supernatant 
from 3 days co-culture of 10^  autologous T cells with or without 2x10^ pre-treated DCs and in 
the presence or absence of SEE (0.2 pg/ml). Asterisks indicate statistical significance, measured 
as indicated in Materials and methods, of TNE-o/DETA-NO DCs vs. TNF-a-treated DCs {n = 
8).
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5.2.2 The effect of nitric oxide on T lymphocyte activation by TNF-a-treated
dendritic cells is dependent on generation of cGMP.
Previously I have shown that NO triggers cGMP generation in immature human 
DCs and that the cyclic nucleotide contributes to regulate endocytosis in these cells. I 
therefore investigated whether the NO-dependent enhancement of DC antigen 
presenting ability was mediated by cGMP. To this end, immature DCs were pre-treated 
with or without TNF-a in the presence or absence of either the membrane-permeant 
cGMP analogue 8 Br-cGMP, DETA-NO, or DETA-NO together with ODQ. DCs 
treated with 8 Br-cGMP and TNF-a induced proliferation of T cells and release of IFN- 
y and IL-2 higher than those induced by TNF-a-treated DCs, with a pattern similar to 
that observed using DCs treated with DETA-NO and TNF-a (Fig. 19).
Pre-treatment with ODQ, while ineffective in DCs treated with TNF-a alone, reversed 
the potentiating effect induced by DETA-NO co-administration with TNF-a on both the 
proliferation of T cells and the release of cytokines (Fig. 19).
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Figure 19 The NO-dependent enhancement of TNF-a-treated DCs to induce T cells
activation is mediated by cGMP
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Immature DCs were incubated for 2 days with or without TNF-a (50 ng/ml) in the presence or 
absence of DETA-NO (50 pM), the membrane permeant cGMP analogue 8  Br-cGMP (3 mM), 
or the inhibitor of soluble guanylate cyclase ODQ (0-5 pM), as indicated in the keys to the 
various panels. 10^  autologous T cells were then co-cultured with or without 2x10* pre-treated 
DCs in the presence or absence of SEB (0.2 pg/ml). T cells activation was evaluated as both 
proliferation (A) and secretion of IFN-y and IL-2 (B and C) after 3 days. Asterisks indicate 
statistical significance, measured as indicated in Materials and methods {n = 8 ).
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5.2.3 A soluble factor released by dendritic cells treated witb TNF-a and nitric 
oxide is responsible for tbe enhanced T lymphocyte activation.
TNF-a-induced differentiation of DCs towards a mature, antigen-presenting 
phenotype involves the co-ordinate up-regulation on the plasma membrane of various 
proteins, including MHC class I and II and co-stimulatory molecules, as well as the 
release of soluble factors (Banchereau et al., 2001).
I examined whether NO modulates plasma membrane expression of MHC class I 
and II, CD la, CD83 and co-stimulatory CD40, CD80 and CD86 molecules. The pattern 
of expression of these molecules in both immature and TNF-a-treated DCs is shown in 
Fig. 20. Treatment of immature DCs for 48 h with DETA-NO alone changed expression 
of neither MHC class I and II, nor any of the co-stimulatory molecules investigated. 
Likewise, the NO donor did not modify the pattern of expression of these molecules 
elicited by a 48 h maturation treatment with TNF-a (Fig. 20).
It is possible to conclude that, at variance with endocytosis, ceramide generation 
and T cell activation, surface protein finger printing induced by TNF-a in DCs is 
established independently of the NO regulation.
Figure 20 Phenotypic characterisation of DCs induced to mature by TN F-a 
administered in the presence or absence of NO
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Immature DCs were treated for 2 days with or without TNF-a (50 ng/ml) in the presence or 
absence of DETA-NO (50 pM). Cells preparations were analysed by flow cytometry after 
staining with FITC-conjugated Abs specific for the surface antigens specified at the top of each 
columns (solid-line histograms). Cell autofluorescence is indicated by the superimposed, thin- 
line histograms. The results shown are from one experiment representative of 10 consistent 
ones.
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Whether release of soluble factors accountes for the effects of NO-treated DCs 
on T cell proliferation was next investigated. Immature DCs were treated for 2 days 
with or without TNF-a in the presence or absence of DETA-NO, washed free of the 
cytokine and the NO donor, and maintained for a further 2 days in culture. Culture 
medium was then removed and assayed for its ability to modulate proliferation of T 
lymphocytes in an activation system consisting of a CD28-activating mAh administered 
together with either SEB or anti-CD3 mAh. Both these activation systems triggered 
significant T cell proliferation responses (Fig. 21). Addition of the supernatant from 
cultures of either untreated DCs or DCs treated with only DETA-NO did not modify 
this activation. By contrast, the supernatant from TNF-a-treated DCs increased T cell 
proliferation (more evidently in the anti-CD28/SEB model). In both the activation 
systems analysed this increased T cell proliferation effect was significantly greater 
using supernatants from DCs co-incubated with TNF-a and DETA-NO (Fig. 21).
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Figure 21 Release of soluble factors is responsible for the enhanced T lymphocytes
activation by DCs pretreated with TNF-a and NO
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Supernatants were collected from DCs pre-treated for 2 days with or without TNF-a (50 ng/ml) 
in the presence or absence of either DETA-NO (50 pM). T cell proliferation in the presence or 
absence of the various supernatants, as indicated on the left hand side of panel B, was stimulated 
for 3 days with either anti-CD3 (1 pg/ml)/anti-CD28 (5 pg/ml) mAbs or SEB (0.2 pg/ml)/anti- 
CD28 mAb, as shown in the scheme of panel A. Control experiments with unstimulated T cells 
were run in parallel
80
5.2.4 Increased release of IL-12 is responsible for tbe enhanced T cell activation
by nitric oxide/TNF-a-treated dendritic cells
Among the pro-inflammatory cytokines released by DCs, IL-12 has been shown 
to play pivotal roles in T cell activation (Ma et al., 2001). We therefore evaluated 
whether the stimulatory effect of NO is mediated by release of IL-12. As shown in 
Figure 22 A, release of the cytokine was slightly increased by pre-treatment of DCs 
with TNF-a alone and further, significantly enhanced when either DETA-NO or 8Br- 
cGMP were co-administered with TNF-a. The dependence on cGMP generation of the 
effect of DETA-NO was further confirmed by the observation that administration of 
ODQ prevented the co-stimulatory effect of DETA-NO administered with TNF-a, 
giving rise to IL-12 generation responses similar to those observed in DCs pre-treated 
with TNF-a alone. Basal IL-12 release was not modified by DC pre-treatment with 
DETA-NO, 8Br-cGMP or ODQ alone. To evaluate whether this increased secretion of 
IL-12 was involved in stimulation of T lymphocyte proliferation by DCs, we tested the 
effect of a neutralising, anti-IL-12 Abs cocktail (Rogge et al., 1997). Inhibition of IL-12 
did not modify significantly T cell proliferation induced by the supernatant from both 
untreated and TNF-a-pre-treated DCs. This applied to both anti-CD28/SEB and anti- 
CD28/anti-CD3-stimulated T cells (Fig. 22 B). In contrast, the neutralising anti-IL-12 
Abs cocktail abolished the enhancing effect on T cell proliferation induced by DETA- 
NO when combined with TNF-a, giving rise to proliferation values similar to those 
observed with TNF-a alone. These effects appeared to be specific because they were 
not observed in the presence of an isotype control Ab.
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Figure 22 Release of IL-12 is crucial to enhanced T lymphocyte activation by DCs 
treated with TNF-a together with NO
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Supernatants were collected from DCs pre-treated for 2 days with or without TNF-a (50 ng/ml) 
in the presence or absence of either DETA-NO (50 pM), 8  Br-cGMP (3 mM) or ODQ (3 pM). 
A: concentration of IL-12p70 in the supernatants was evaluated by ELISA.
B: T cell proliferation in the presence or absence of the various supernatants, as indicated on the 
left hand side, was stimulated for 3 days with either anti-CD3 (1 pg/ml)/anti-CD28 (5 pg/ml) 
mAbs or SEB (0.2 pg/ml )/anti -CD28 mAb. Control experiments with un stimulated T cells were 
run in parallel. Experiments were carried out as in the absence (nil) or presence (aIL-12) of an 
IL-12 neutralising mAb cocktail, as described in the Methods section. Experiments with an 
isotype control Ab were carried out in parallel. Asterisks indicate statistical significance, 
measured as indicated in Materials and methods; s.n. statistically not significant (n = 6 ).
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5.2.5 Nitric oxide enhances by cGMP-dependent IL-12 release the T lymphocyte
activation by dendritic cells matured with either LPS or an anti-CD40 mAh.
To assess whether the effect of NO and the mechanism of its action are specific 
for TNF-a-induced DC maturation or constitute a more general phenomenon, I 
investigated DC maturation induced by either LPS or activation of CD40. Immature 
DCs were treated for 2 days with or without LPS (1 pg/ml) or an anti-CD40, activating 
mAb (10 pg/ml) in the presence or absence of DETA-NO, 8 Br-cGMP, and ODQ, 
administered in various combinations. The cells were then washed free of all the 
treatments. When DETA-NO was administered to DCs together with either LPS or the 
anti-CD40 mAb, the NO donor increased DC induced stimulation of T cells, both in 
MLRs (Fig. 23, A and B) and in autologous reactions in the presence of SEB (Fig. 23, C 
and D). Similar to the experiments with TNF-a, in the experiments with LPS- and anti- 
CD40-treated DCs I found that all the effects of NO were dependent on cGMP 
generation, since they were mimicked by 8 Br-cGMP and reversed by ODQ (Fig. 23, C 
and D).
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Figure 23 NO enhances the ability of LPS- and anti CD40 mAb-treated DCs to 
induce T cell activation
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Immature DCs were treated for 2 days with or without either LPS (1 pg/ml, panels A and C) or 
an anti-CD40 mAh (10 pg/ml, panels B and D) in the presence or absence of DETA-NO (50 
pM), 8  Br-cGMP (3 mM) or ODQ (3 pM). (A and B) These pre-treated DCs were co-cultured 
at the indicated ratios with a fixed number of allogeneic T cells (10^ cells/well); proliferation 
(■^H-thymidine incorporation in T cells) was measured after 5 days of DC/T cell co-culture. (C 
and D) 2x10"^  pre-treated DCs were co-cultured with 10^  autologous T cells in the presence of 
SEB (0.2 pg/ml) or without any stimulus. Proliferation was measured after 3 days. Asterisks 
indicate statistical significance, measured as indicated in Materials and methods {n = 6 ).
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Both LPS treatment and CD40 cross-linking triggered DC maturation, as assessed by 
increased expression of CD80, CD83, CD86 and MHC class II, and none of which was 
modified by co-treatment of the cells with DETA-NO (Fig 24).
Figure 24 Phenotypic characterisation of DC maturation induced by LPS or by 
CD40 cross-linking in the presence or absence of NO
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Immature DCs were treated for 2 days with or without LPS (1 pg/ml) or an anti-CD40 mAb (10 
pg/ml) in the presence or absence of DETA-NO (50 pM). Cell preparations were analysed by 
flow cytometry after staining with FITC-conjugated Abs specific for CD80, CD83, CD8 6  and 
MHC class II. Values shown are the relative fluorescence intensities ± SEM measured for each 
FITC-conjugated Abs vs. cell autofluorescence (« = 6 ).
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Since these effects of NO were similar to those observed in TNF-a-treated DCs, 
I investigated whether they were due to IL-12 release. As already reported (Celia et al., 
1996), treatment of DCs with either LPS or anti-CD40 Ab résultés in the release of IL- 
12 amounts greater than those observed after DC treatment with TNF-a. These values 
were further, significantly increased by the co-incubation of DCs with LPS or anti- 
CD40 together with DFTA-NO (Fig. 25, A and D). All the co-stimulatory effects of NO 
on the production of IL-12 induced by LPS- and anti-CD40 were also dependent on 
cGMP generation, since they were mimicked by 8 Br-cGMP and reversed by ODQ (Fig. 
25, A and D).
I then investigated the effects on T cell proliferation in the anti-CD28/SFB 
system of supernatants obtained from 2 day cultures of DCs stimulated with either LPS 
or anti-CD40 mAb, prepared as described above for the experiments with TNF-a. Both 
conditions gave rise to T cell proliferation, which was significantly increased when 
supernatants were obtained from DCs incubated also with DFTA-NO (Fig. 25, B and 
F). Administration of the neutralising anti-IL-12 Ab cocktail reduced T cell 
proliferation induced by the supernatant from either LPS or anti-CD40-pre-treated DCs, 
and abolished the further enhancing effect induced by DFTA-NO.
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Figure 25 Release of IL-12 is crucial to NO-potentiation of the T lymphocyte
activation responses by DCs treated with either LPS or anti-CD40 mAb
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Supernatants were collected from DCs pre-treated for 2 days with or without either LPS (1 
|4g/ml, panels A and B) or an anti-CD40 mAb (10 |4g/ml, panels D and E) in the presence or 
absence of either DETA-NO (50 pM), 8 Br-cGMP (3 mM) or ODQ (3 pM). (A and D) 
Concentration of IL-12p70 in the various supernatants was evaluated by ELISA. (B and E) T 
cell proliferation in the presence or absence of the various supernatants, as indicated on the left 
hand side, was stimulated for 3 days with SEB (0.2 pg/ml)/anti-CD28 mAb, in the absence (nil) 
or presence of an IL-12 neutralising mAb cocktail (aIL-12), as described in the Methods 
section. Experiments with an isotype control Ab were carried out in parallel. Asterisks indicate 
statistical significance, measured as indicated in Materials and methods {n = 6). (C) T cell 
proliferation was stimulated for 3 days with SEB (0.2 pg/ml)/anti-CD28 mAb, in the presence 
of increasing concentrations of IL-12 (0-1000 pg/ml) {n = 5).
To further evaluate the role of released IL-12, I measured the effects of adding 
increasing concentrations of exogenous IL-12 to T lymphocytes in the anti-CD28/SEB 
experimental system. As shown in Fig. 25 C, IL-12 increased T cell proliferation in a 
concentration-dependent manner. Moreover, the effects of exogenous IL-12 appeared in 
the range of those induced by supernatants containing comparable concentrations of 
endogenously generated IL-12 (compare panel C in Fig. 25 with panels B and E in the 
same Fig. and with panel B in Fig. 22).
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6 DISCUSSION
During the past twenty years, NO has been recognized as one of the most 
versatile players active on the immune system. This short-lived messenger is generated 
during immune responses mainly by iNOS, expressed in phagocytes after their 
activation by cytokines and bacterial products (Moncada et al., 1995). The effects of NO 
on the immune system are multiple and complex. NO endows activated macrophages 
and microglial cells with anti-microbial and cytotoxic activity, influences the function 
of mast cells, neutrophils, T and NK cells, and regulates the generation of cytokines and 
chemokines at the site of infection (Bogdan 2001). Targeted deletion of iNOS renders 
mice more susceptible to infections (Wei et al., 1995). Invading pathogens and/or 
inflammatory stimuli, e.g. TNF-a, LPS and IL-IB, elicit maturation of DCs; 
simultaneously, in inflamed peripheral tissues DCs are exposed to a variety of signals, 
among which is NO (MacMicking et al., 1997; Bogdan 2001). Although DCs are 
considered to have a central role in the induction of specific immune response, so far 
there is still little information about how NO can affect human DC function. My PhD 
project was aimed at investigating the role of NO during DC maturation. This complex 
process is characterized by profound changes in DCs: downregulation of endocytic 
ability; increased expression of costimulatory molecules, MHC class I and II; increased 
efficiency in inducing T cell stimulation. In the first part of my thesis I have 
concentrated the investigation on the effects of NO on the endocytic activity of DCs 
exposed to a maturation stimulus, and on the mechanism of NO action in the regulation 
of this process. I have used immature human monocyte-derived DCs which efficiently 
endocytose antigens in vitro (Sallusto et al., 1994). These cells were exposed to TNF-a
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which triggers an in vitro maturation process, as confirmed by the concentration- 
dependent reduction of endocytic activity and by the upregulation of molecules 
involved in T cell activation (Banchereau et ah, 1998; Sallusto et ah, 1994). Endocytosis 
was studied by cell exposure to FITC-dextran. As a source of NO I used both NO 
donors and the murine microglial N9 clone cells, which expresses iNOS after tratment 
with INF-y and polystirene microspheres. The microglial-DC cocultures offer the 
opportunity of a confinons release and a physiological source of NO. In immature DCs 
NO, generated either by activated N9 phagocytes or by two NO donors, DETA-NO and 
SNAP, did not modify endocytosis per se. In the presence of TNF-a, however, NO 
reversed the inhibitory effect of the cytokine, i.e. it maintained the ability of DCs to 
internalise FITC-dextran. Soluble guanylate cyclase, a heterodimeric enzyme that 
converts GTP to cGMP, is a well known receptor of NO, and mediates the effects of this 
gaseous molecule in many physiological system (Denninger et al., 1999). DETA-NO 
activates soluble guanylate cyclase in immature DCs, leading to a subsequent increase 
in the concentration of cGMP. Accumulation of this mediator is prevented when DCs 
are treated with the NO donor in the presence of the soluble guanylyl cyclase inhibitor 
ODQ. Since NO effect on endocytosis was prevented by ODQ, and mimicked by the 
membrane permeant analogue of cGMP, 8-Br-cGMP, I conclude that NO acts via a 
cGMP-dependent mechanism.
Maturation of DCs is triggered by TNF-a via activation of its p55 receptor 
(Sallusto et al., 1995), which induces in many cell types sphingomyelin breakdown with 
resulting accumulation of the lipid messenger ceramide (Kolesnick et al., 1998; Perry et 
al., 1998). Involvement of the latter in the inhibition of endocytosis was documented by 
previous studies with immature DCs, where ceramide inhibited endocytosis of various
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substrates, namely lucifer yellow, horseradish peroxidase and FITC-dextran, suggesting 
its role as the messenger by which TNF-a downregulates this process (Sallusto et ah, 
1996). I thus investigated whether the maintenance by NO of the endocytic ability in 
TNF-a-treated DCs was due to inhibition of ceramide accumulation. Consistent with 
this possibility, I found that TNF-a induced a time-dependent accumulation of 
ceramide, which was inhibited by both NO donors and NO released by activated N9 
cells. Again cGMP generation accounted for this effect of NO, as demonstrated by 
experiments with ODQ and 8-Br-cGMP.
In order to analyse whether inhibition of ceramide accumulation by NO was the 
only event responsible for its ability to reverse the effect of TNF-a on the endocytic 
ability of DCs, experiments were carried out with the membrane permeant C2-ceramide. 
This lipid inhibited endocytosis of FITC-dextran in a persistent way, however NO and 
8-Br-cGMP were still able to reverse this effect. This finding indicates that the action of 
NO on endocytosis can be explained not only by its cGMP-dependent inhibition of 
ceramide accumulation but also by additional effects, mediated through cGMP, on the 
signal transduction pathway activated by TNF-a taking place after the biogenesis of 
ceramide. The molecular target(s) of this further action by NO/cGMP remain(s) to be 
established. These results indicate that the inhibition by NO, via cGMP, of the TNF-a- 
induced downregulation of endocytosis is exerted at multiple levels along the signal 
transduction cascade triggered by this cytokine. Nitric oxide and cGMP function 
therefore as wide inhibitors of the action of TNF-a on endocytosis rather than as 
selective regulators of one single transductional event.
Nitric oxide generation in peripheral tissues occurs as a consequence of various 
stimuli (MacMicking et ah, 1997; Moncada et al., 1995; Liew 1995; MacLean et al..
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1998). The regulation of DC endocytosis by NO through cGMP might enable these cells 
to prolong their antigen uptake function at the site of inflammation and therefore modify 
the ensuing immune responses in the lymphoid organs. So far, the role of NO in the 
maturation process of DCs has been investigated in vitro in the murine system, by 
measuring antigen presentation as well as the ensuing T cell proliferation after DCs 
exposure to cytokines, which results in expression of iNOS by DCs (see e.g. Lu et al., 
1996). In these systems a reduction in allostimulation was observed at high DC:T cell 
ratio, and correlated with increasing concentration of NO. It was also demonstreted an 
induction of apoptosis in DCs by NO (Bonham et al., 1996). These findings suggest an 
inhibitory role for NO on DC ability to induce an immune response. Regulation by NO 
of human DC function appears, however, to be different. To my knowledge, iNOS 
expression and NO generation by these cells had not been reported except in primary 
biliary cirrhosis and hepatocellular carcinoma (Yamamoto et al., 1998; Ninomiya et al.,
1999). Consistent with most previous results, I could detect neither expression of iNOS 
nor NO generation by human DCs exposed to various combinations of cytokines and 
LPS. Regulation of human DCs might therefore depend on exogenous NO, generated at 
the site of infection by macrophages as a result of their activation by cytokine during the 
inflammatory response (Mclnnes et al., 1996). Since the functional effects of TNF-a on 
human DCs appear to be reversible and re-inducible (Nelson et al., 1999), NO might 
maintain active endocytosis of antigens as long as DCs are confined to the inflammation 
site, tuning their response to this cytokine and possibly also to other maturative stimuli. 
After leaving the inflammation site, DCs would no longer be exposed to NO, and could 
therefore down-regulate their endocytic ability to prevent any interference by irrelevant 
self-antigens captured during migration to lymphoid organs (Banchereau et al., 1998).
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Thus NO, acting on human DCs in a paracrine fashion appears to contribute enhancing 
the immune responses, whereas disregulation of its homeostasis, with its generation 
under severe pathological conditions in DCs (Wang et ah, 2001; Yamamoto et ah, 1998; 
Ninomiya et ah, 1999), might instead impair the immunological function of these cells. 
A hypothetical model for this action by NO is in Figure 26.
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Figure 26 Proposed model of the effect of NO on DCs during their maturation 
process
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In the second part of my project I have adressed the possibility that NO affects 
other events involved in the maturation process of human DCs; in particular I have 
focused my attention on NO modulation of DC ability to induce T cell activation.
Recent reports demonstrated that NO, acting in a dose dependent manner, plays an 
important role in the selective regulation of immune response by modulating T cell 
functions and differentiation. Low doses of NO can enhance the induction of Thl cell 
differentiation by IL-12 and antigens, wherease high doses of NO inhibit the induction 
of the same cells (Niedbala et al., 1999). Cohen et al. have investigated the role of NO 
in the human lymphocyte responses to bacterial superantigen. They demonstrated that 
NO is an essential requirement for lymphocytes proliferation and lymphokine release 
induced by superantigen stimulation of human mononuclear cells. In addition, they 
found a marked difference in nitrite production between superantigen-stimulated murine 
splenocytes and human mononuclear cells. While cultured murine splenocytes 
stimulated with mitogens can produce nitrite concentrations of 20 to 100 |iM, nitrite 
production by superantigen-stimulated human mononuclear cells remains at the lower 
limit of detection. Nitric oxide concentration could explain the discrepancy with 
previous findings in the mouse, where NO was shown to act as an inhibitor of 
superantigen induced activation (Sriskandan et al., 1996). So far, even if NO appears to 
be a modulator of T cell specific immune responses there are no clear studies describing 
if NO can influence T cell responses by acting on DC function. In view of my findings 
that, at variance with their murine counterparts, DCs from healthy human donors are 
unable to express iNOS, I designed the experimental protocol to mimick the in vivo 
situation of human DCs exposed only to NO generated at the site of inflammation by 
neighbouring, NOS-competent cells. Accordingly, I exposed DCs to NO only during
96
their maturation, which was triggered by three different stimuli, TNF-a, LPS and an 
activating, anti-CD40 mAb. The NO donor and the maturation stimuli were then 
removed before initiating the co-colture of DCs with T lymphocytes. This approach has 
allowed not only to mimick the effects of a temporary exposure of human DCs to the 
gaseous messanger, but also to dissect the effects of NO which are accounted for by a 
direct action on DCs. Under these conditions I found that NO, while ineffective when 
administered alone, synergises with each of the three maturation stimuli to trigger a 
modified DC maturation programme, which results in an enhanced DC ability to 
stimulate T lymphocyte proliferation. This effect of NO has three characteristics. It is 
independent of actions on antigen uptake/processing, since it was observed in MLRs 
and in autologous reactions occurring in the presence of SEB, anti-CD3 mAb or PPD. 
Nitric oxide effect was observed also with the supernatant of DCs pretreated with the 
different maturation stimuli in the aCD3/aCD28 T cell activation system, which is 
independent of the presence of DCs. In addition, the enhanced DC ability of stimulating 
T lymphocyte proliferation was found to persist after removal of NO. This latter result 
suggests that priming with NO in peripheral tissues may be sufficient to exert a 
licensing effect on antigen presentation in lymphoid organs. Furthermore, the effect of 
NO appears independent of the stimulus that triggers DC maturation since it was 
equally observed with LPS, TNFa or the anti-CD40 mAb. This, together with the 
observation that the increased ability by NO to activate T cells was only observed when 
both NO and each of the above stimuli were co-administered to DCs, indicates that the 
gas acts through regulation of specific transductional events activated by these 
maturation stimuli. Paracrine NO, therefore, appears to function as a co-signal 
influencing the cross-talk between DCs and T cells (Fig 26).
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I also investigated the possible mechanism and signaling events through which 
NO exerts its action on maturing DCs. Similarly to what has already been described for 
the regulation of DC endocytosis, I found that the effect of NO depends on the 
activation of guanylate cyclase and generation of cGMP, as demonstrated by 
experiments with 8-Br-cGMP and ODQ. As far as the signaling events regulated by 
NO/cGMP I did not observe any modification in the maturation-regulated expression of 
MHCs and/or major co-stimulatory molecules. However, I found that NO modified the 
ability of DCs to release molecules to the extracellular milieu. This was clearly shown 
by experiments carried out using supernatants from DCs treated with the maturation 
stimuli TNFa, LPS and anti-CD40 mAbs. When DCs were treated with these stimuli in 
the presence of NO, the supernatants showed enhanced ability to induce proliferation of 
T lymphocytes activated with the antiCD3/antiCD28 mAbs or SEB/antiCD28 mAb in 
the absence of APC. I then investigated the nature of released substances involved in 
mediating the effects of NO on the DC-T cell system. With all three maturation stimuli 
tested I identified the increased release of IL-12 by DCs as the relevant event occurring 
in response to the cGMP-dependent effect of NO. I studied the involvement of IL-12 by 
two experimental approaches. In the first, IL-12 neutralising Abs, when added to the 
supernatants from the various DC cultures, were found to inhibit the enhancing effect of 
NO on T cell proliferation. In the second approach, IL-12 added to T lymphocytes in the 
anti-CD28/SEB system was shown to trigger T cell proliferation in a concentration- 
dependent fashion, as already reported in a similar system (Kubin et al., 1994). This 
effect was in the range of that induced by supernatants containing comparable 
concentrations of IL-12 endogenously produced by DCs exposed to NO and either LPS, 
TNFa or the anti-CD40 mAb. From these two experimental approaches I concluded that
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increased release of IL-12 explains the observed effect of NO/cGMP-treated DCs on T 
lymphocyte proliferation.
Activation of guanylate cyclase and generation of cGMP mediate many effects 
of NO in a variety of cells, including signalling events activated by TNFa and LPS 
(Bulotta et al., 2001; Browning et al., 1999; Harbrecht et al., 1995; De Nadai et al.,
2000). Despite the relevant role played by NO/cGMP in immune responses, however, 
evidence about cGMP regulating maturation signal transduction pathways in DCs had 
not been reported. The findings I describe here, showing a cGMP-dependent inhibition 
by NO of the TNF-a-triggered ceramide generation with maintenance of endocytosis, 
together with the identification of IL-12 as a target of the NO/cGMP action in three 
distinct signal transduction pathways, may provide a clue for elucidating the molecular 
events regulated by the cyclic nucelotide during DC maturation.
Generation of IL-12 by DCs is known to be a tightly regulated event (Ma et al.,
2001). Production of this cytokine can be elicited by most pathogens and increased 
further by activated CD40 ligand-positive T cells (Schulz et al., 2000). This soluble 
mediator is able to activate NK and T cells for the induction of IFN-y production and 
cytolytic activity. In part through its induction of IFN-y production, IL-12 enhances the 
phagocytic and bactericidal potential of phagocytes and their ability to release 
proinflammatory cytokines such as IL-lp, IL-6, TNF-a and IL-12 itself. In addition to 
its role in mobilizing the first line of defense, IL-12 produced during the early phases of 
an infection is also fundamental for the ensuing antigen-specific immune response by 
promoting the differentiation and function of T helper 1 (Thl) cells that support cell- 
mediated immunity, cytotoxic T cell generation and activation of phagocytic cells. 
Particularly in the presence of costimulation, IL-12 is also a potent mitogen for T and
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NK cells (Ma et al., 2001). Although IL-12 secretion occurs commonly during DC 
maturation, there are specific situation in which this does not occur. For example, DCs 
matured in the presence of cholera toxin or CD95 ligand fail to secrete IL-12 (Rescigno 
et al., 2000). Similarly, pro-inflammatory cytokines such as EL-1(3 and TNF-a, appear 
poor activators of IL-12 secretion, as also shown by my results (Rescigno et al., 2000). 
The results I have obtained with TNF-a, however, provide evidence that this phenotype 
can be reversed in the presence of NO.
LPS, TNF-a and CD40 ligand are capable of upregulating iNOS in immune cells 
competent to express the enzyme, with subsequent, sustained generation of NO (Bogdan
2001). Nitric oxide, therefore, might be part of a feed-forward loop aimed at amplifying 
immune responses through an increased antigen presenting function of DCs. This novel 
function of NO might contribute to explain the mechanisms by which cooperation 
among IL-12, NO and other Thl-type cytokines play an important role in healing of in 
vivo infections (Das et al., 2001; Perez-Santos et al., 2001; Uzonna et al., 2001; 
Wilhelm et al., 2001).
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6.1 Concluding remarks and future directions
Protective immunity results from the complementary contributions of two 
fundamental systems: innate and adaptive immune system. The interplay between these 
systems is critical for the successful detection and elimination of infectious pathogens. 
Macrophages, NK cells and DCs are sentinels which control pathogen entry and 
coordinate early defence by innate, and later by the acquired, immune system. At the 
interface between the innate and the adaptive immune system lies NO, which has been 
demonstrated to be produced in birds, molluscs, horseshoe crabs, insects, protozoa, and 
slime molds (MacMicking et al., 1997). Its role in immunity is highly conserved over 
the course of evolution, supporting the hypothesis of the common evolutionary origin of 
the natural immune and inflammatory response (MacMicking et al., 1997; Bogdan et al.,
2000). Indeed NO is not only a necessary component of non-specific, innate defence 
mechanisms against pathogens but also modulates several functions of immune 
competent cells involved in the adaptive responses during inflammation. Thus, NO 
appears to play both regulatory and effector roles. The work here presented provides 
first insights about how NO exerts a modulatory role on DCs, both at the level of 
intracellular signalling events and in terms of final effect on DC function. These 
findings describe two novel NO functions that link innate and adaptive immunity: NO 
as a modulator of DC endocytosis, inducing increased uptake of putative antigens, and 
at the same time as an enhancer of DC ability to activate specific T cell responses. So 
far, various mechanisms by which DCs were able to adapt their properties as a function 
of their localization and intercellular interactions have been demonstrated. Our results 
introducing NO as a novel regulator of DCs suggest new interesting perspectives, 
because of peculiar aspects of its generations and unique physico-chemical properties.
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Our results may open the way to the identification of others intracellular targets, which 
can mediate NO effects in DCs and to the fine characterization of signalling events 
modulated by NO during DC maturation induced by various stimuli. Another interesting 
aspect is the identification of DC plasma-membrane molecules regulated by NO and 
involved in DC-T cells interections. It will be also important to investigate whether NO 
regulates another key event in maturation of DCs, i.e. their migration to lymphoid 
organs. A fascinating hypothesis is that NO regulates expression of chemokines 
receptors and adhesion molecules which are known to be modulated during maturation 
stimuli in order to allow egress from the site of inflammation and migration to 
lymphonodes (Sallusto et al., 1998).
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7 EXPERIMENTAL PROCEDURES
7.1 Materials
The following reagents were purchased as indicated: mouse monoclonal anti- 
iNOS from Transduction Laboratories (Lexington, KY); horseradish peroxidase (HRP)- 
conjugated goat anti-mouse IgG antibodies (Abs) from Santa Cruz Biotechnology 
(Santa Cruz, CA); fluorescein-iso-thiocyanate (FITC)-labelled mouse monoclonal Abs 
anti-human CD la, MHC class I and class II, CD80, CD83, CD86, CD40 and CD 14 
from Caltag (Burlingame, CA);. y ^ ^P-ATP and the cGMP radioimmunoassay kit from
(Boston, MA); the Enhanced ChemiLuminescence kit from Amersham 
Corporation (Little Chalfont, UK); recombinant human TNF-a, (Z)-l-[2-(2- 
aminoethyl)-N-(2ammonioethyl) amino]diazen-l-ium-1,2 diolate (DETA-NO) and H- 
[l,2,4]oxadiazolo[4,3-a]quinoxalin-l-one (ODQ) from Alexis Italia (Florence, Italy); 
diacylglycerol kinase from BIOMOL (Hamburg, Germany); C% ceramide, 
aminoguanidine and S-nitroso-acetylpenicillamine (SNAP) from Calbiochem (Bad 
Soden, Germany); recombinant human interleukin-4 (IL-4) from Strathmann Biotech 
GMBH (Hannover, Germany); recombinant human Granulocyte Macrophage Colony- 
Stimulating Factor (GM-CSF) from Mielogen-Schering Plough (Milan, Italy); 
recombinant mouse and human interferon-y (IFNy) from Genzyme (Cambridge, MA); 
FITC-dextran (Mr = 40,000) from Sigma (Milan, Italy); Ficoll from BioChrom (Berlin, 
Germany); Percoll from Pharmacia Biotech (Milan, Italy); polybed polystirene 
microspheres from Polyscience Inc. (Milan, Italy). The reagents for tissue culture were 
from GIBCO (Basel, Switzerland) except for foetal calf serum (clone III), obtained from 
Hyclone-Celbio, (Milan, Italy). The N9 murine microglial cells were kindly provided by
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Paola Ricciardi-Castagnoli (Milan, Italy). The mAh anti-human CD28 was from Becton 
Dickinson (San José, CA); methyl-^H thymidine from Amersham Pharmacia Biotech 
(Buckinghamshire England); Mycobacterium tuberculosis-dtûyç^à tuberculin purified 
protein derivative (PPD) from Statens Serum Institut (Copenhagen, Denmark); magnetic 
Dynabeads M-450 goat anti-mouse IgG from Dynal (Oslo, Norway); the anti-human IL- 
12 neutralising mAbs (clones 17F7 and 20C2) were kindly provided by Lars Rogge 
(Roche Milano Ricerche, Milan, Italy). The anti-CD40 mAh, purified from the 626.1 
hybridoma, was kindly provided by D. Vercelli (Tucson, AZ, USA). The mAh anti­
human CD3 was purified from the hybridoma (0KT3) obtained from American Type 
Culture Collection (Rockville, MD). Staphylococcus aureus Cowen strain B (SEB) and 
all of the other reagents were from Sigma (Milan, Italy).
The conditions of use of DETA-NO, 8 Br-cGMP and ODQ were selected on the 
basis of previous experiments in monocytes and macrophages. In particular, at the 
concentrations employed in this study, these compounds appear to be not toxic while 
still able to trigger biological effects (Clementi et al., 1998; Orsi et al., 2000).
All solutions were prepared endotoxin-free. Endotoxin contamination in all drug 
solutions was routinely assessed by the Lymulus amoebocyte gélification test, carried 
out according to the manufacturer’s instructions (FBI, Milan, Italy), before 
administration to DCs. All reagents, including the medium, scored negative.
7.2 Preparation of immature and mature dendritic cells
Peripheral blood mononuclear cells from healthy blood donors were obtained 
either from huffy coats (kindly provided by the Blood Transfusion Department of our 
Institution) or heparinised blood drawn by venipuncture. Standard gradient separation
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procedures on Fycoll-Paque were used (Sallusto et al., 1994). PBMC were resuspended 
in RPMI-1640 containing 10 % FCS, 2 mM glutamine 100 U/ml penicillin 100 pg/ml 
sptreptomycin, from hereon referred to as “complete medium”, and allowed to adhere 
on 6-well plates (Costar, Cambridge, MA) for 1 h at 37°C in a humidified 5% CO2 
atmosphere. Non-adherent cells were discarded. In order to derive immature DCs, 
PBMC were then cultured for 7 days in complete medium, in the presence of human 
GM-CSF (50 ng/ml) and IL-4 (1000 U/ml). Cells were refed with fresh complete 
medium contening GM-CSF and IL-4 on days 2, 4, and 6. Depletion of residual T 
lymphocytes from immature DCs was routinely carried out by incubating the cell 
preparations with the anti-CD3 mAh (1 pg/10^ cells) and goat anti-mouse IgG-coated 
Dynabeads M-450. Anti-CD3 mAb-bound T cells were removed with a magnet 
according to manufacturer’s instructions. Purified DC preparations were routinely 
checked for contaminating lymphocytes by flow cytometry using a fluorescence- 
activated cell sorter (FACScan plus, Becton Dickinson, Sunnyvale, CA). Residual 
lymphocytes accounted for less than 1 % of total cells (not shown). Mature DCs were 
obtained from immature DCs by a 48 h incubation in complete medium in the presence 
of human TNF-a (0.2-200 ng/ml), anti-CD40 mAh (10 pg/ml) and LPS (1 pg/ml). 
Similar conditions were used in the experiments in which C2-ceramide (80 pM) was 
used. In the experiments in which DCs were incubated with TNF-a, LPS and anti-CD40 
mAh maturation was routinely assessed by flow cytometry, measuring the exposure on 
the plasma membrane of specific antigens known to be expressed by immature or 
mature DCs, namely CD la, a marker of human myeloid DCs; MHC class I and class II 
molecules; CD80 and CD86, involved in T cell co-stimulation (Sallusto et al., 1994) 
(Chen et al., 1998). Expression of these antigens was analysed after staining with
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appropriate FITC-labelled Abs as described later. Figure 27 shows results from a typical 
analysis: GM-CSF, IL-4- treated (immature) DCs express CD la, MHC class I and class 
II, CD80, CD86 and CD40. TNF-a-treated (mature) DCs show a significant 
upregulation of MHC class I and class II, CD la, CD80, CD86 and CD40. Expression of 
the macrophage marker CD 14 was never observed. Viability and apoptosis in the 
various samples was assessed at different times by propidium iodide/annexin V staining 
exactly as described (Rovere et al., 1996).
When the 48 h incubation with either TNF-a or C2-ceramide was carried out in the
presence of DETA-NO (100 pM), SNAP (200 pM), 8-Br-cGMP (3 mM) or ODQ (3 
pM), the compounds were added in various combinations 10 min before and were 
maintained throughout the incubation time. Control experiments in which DCs were 
incubated with the various compounds in the absence of TNF-a and C2-ceramide were
carried out in parallel. In the experiments in which cells were exposed to DETA-NO 
and SNAP, they were dissolved immediately before addition to the cells. SNAP and 
DETA-NO prepared 7 days before the experiments were used in control experiments. 
Under these conditions they do not release any NO, as measured using a NO detecting 
electrode with a sensitivity of 1 nM (Mark-2 ISO NO, World Precision Instruments, 
Sarasota, FL). Before the co-culture with lymphocytes, DCs were washed twice in 
complete medium, to remove all the various compounds, and then irradiated (2500 rad). 
Removal of the NO donor was routinely checked by verifying absence of NO 
generation in washed DC suspensions using a NO electrode (Clementi et al., 1998).
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Figure 27 Phenotypic characterisation of human DCs exposed to TNF-a.
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Human monocytes were treated with GM-CSF (50 ng/ml) and IL-4 (1000 U/ml) for 7 days to 
obtain immature DCs. These cells were then incubated with or without TNF-a (200 ng/ml) for 
further 48 h (right and left columns, respectively). Cell preparations were stained with FITC- 
conjugated Abs for surface antigens, as specified on the left hand side, and analysed by flow 
cytometry as described in the Experimental procedures (filled histograms). Their relative 
fluorescence intensity (RFl) was calculated vs negative controls (open histograms). The results 
shown are from one representative experiment.
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7.3 Co-culture of dendritic cells and nitric oxide-generating N9 cells
Exposure of DCs to a continuous flux of NO was achieved in vitro using the 
scavenger murine microglial brain N9 clone cells derived from embryonic mouse, 
which express iNOS upon activation (Corradin et al., 1993). N9 cells were cultured in 
Iscove’s modified DMEM containing 10% foetal calf serum, 100 pg/ml penicillin, 100 
pg/ml streptomycin, 2 mM L-glutamine. Induction of iNOS by these cells requires IFN- 
y together with a second signal (Corradin et al., 1993). To induce iNOS expression, N9 
cells (2 X 10^  cells/ml) were incubated for 24 h in the presence of polybed polystirene 
microspheres (microsphere/cell ratio = 5) and mouse IFN-y (10 U/ml), with or without
the NOS inhibitors aminoguanidine (1 mM) and N®-nitro-L-arginine methyl ester (L- 
NAME; 1 mM). Nitric oxide production by N9 cells was measured by determining the 
nitrite accumulation in the culture medium using the Griess reaction (Green et al., 
1982). Standard curves with increasing concentrations of sodium nitrite were run in 
parallel. The co-colture of DCs and N9 cells was carried out using a double chamber 
system (Costar, Cambridge, MA). A semi-permeable polycarbonate membrane with a 
cut-off of 0.4 pm separated the lower chamber, containing immature DCs, from the 
upper chamber. Dendritic cells were incubated for 48 h in the lower chamber at a 
density of 1 x 10  ^ cells/well either in the presence or absence of human TNF-a (200 
ng/ml). Activated, iNOS-expressing N9 cells were seeded in the upper chamber at a 
density of 2.5 x 10^  cells/well at the beginning of the incubation with TNF-a. Dendritic 
cells were then collected and endocytosis of FITC-dextran was measured as described 
below.
108
7.3 Co-culture of dendritic cells and nitric oxide-generating N9 cells
Exposure of DCs to a continuous flux of NO was achieved in vitro using the 
scavenger murine microglial brain N9 clone cells derived from embryonic mouse, 
which express iNOS upon activation (Corradin et al., 1993). N9 cells were cultured in 
Iscove’s modified DMEM containing 10% foetal calf serum, 100 pg/ml penicillin, 100 
pg/ml streptomycin, 2 mM L-glutamine. Induction of iNOS by these cells requires IFN- 
y together with a second signal (Corradin et al., 1993). To induce iNOS expression, N9 
cells (2 X 10^  cells/ml) were incubated for 24 h in the presence of polybed polystirene 
microspheres (microsphere/cell ratio = 5) and mouse IFN-y (10 U/ml), with or without
the NOS inhibitors aminoguanidine (1 mM) and N®-nitro-L-arginine methyl ester (L- 
NAME; 1 mM). Nitric oxide production by N9 cells was measured by determining the 
nitrite accumulation in the culture medium using the Griess reaction (Green et al., 
1982). Standard curves with increasing concentrations of sodium nitrite were run in 
parallel. The co-colture of DCs and N9 cells was carried out using a double chamber 
system (Costar, Cambridge, MA). A semi-permeable polycarbonate membrane with a 
cut-off of 0.4 pm separated the lower chamber, containing immature DCs, from the 
upper chamber. Dendritic cells were incubated for 48 h in the lower chamber at a 
density of 1 x 10  ^ cells/well either in the presence or absence of human TNF-a (200 
ng/ml). Activated, iNOS-expressing N9 cells were seeded in the upper chamber at a 
density of 2.5 x 10  ^cells/well at the beginning of the incubation with TNF-a. Dendritic 
cells were then collected and endocytosis of FITC-dextran was measured as described 
below.
108
7.4 Flow cytometric analysis
To assess DC phenotype after the various stimuli, cells were washed with PBS 
and then 5 x 10  ^ cells were incubated for 30 min at 4°C in PBS containing 1 % FCS 
with FITC-conjugated mAh specific to MHC class I, MHC class II, CDla, CD 14, 
CD40, CD80, CD83 or CD86. Cells were then washed and resuspended in 300 ul of 
cold PBS containing 1 % FCS. Expression of the various molecules was evaluated by 
flow cytometry using a fluorescence-activated cell sorter (FACStar Plus, Becton 
Dickinson, Sunnyvale, CA) . Residual limphocytes and cellular debris were eliminated 
from the analysis using a gate on forward and side scatter. A minimum of 10"^  DCs were 
analyzed for each sample. Results were processed with a Cell Quest software (Becton 
Dickinson).
7.5 Analysis of endocytosis of FITC-dextran
Dendritic cells, exposed to the various treatments described in the paragraphs 
above, were washed and resuspended in complete medium. 2 x 10  ^ cell/samples were 
incubated in 200 ul medium at either 37 or 4°C with FITC-dextran (1 mg/ml). Uptake of 
the fluorescent dye was stopped at the indicated time-points by the addition of ice-cold 
phsophate buffered saline containing 1% foetal calf serum. Samples were then washed 
three times in the same buffer at 4 °C and analysed by flow cytometry using propidium 
iodide to exclude dead cells as described (Lutz et al., 1997). FITC-dextran, reconstituted 
in RPMI and stored at 4°C, was centrifuged to remove aggregates before addition to the 
cells.
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7.6 Measurement of cGMP generation
Immature DCs (1 x 10  ^ cells/sample), incubated for 15 min at 37 C° in 
phosphate buffered saline with the phosphodiesterase inhibitor hydroxy buthyl methyl 
xanthine (0.6 mM), were incubated for an additional 15 min in the presence or absence 
of DETA-NO (100 pM), with or without ODQ (3 pM). The reaction was terminated by 
addition of ice-cold trichloroacetic acid (final concentration: 7.5 %). After ether 
extraction, cGMP levels were measured using a radioimmunoassay kit and normalised 
on cellular proteins, determined by the bicinchoninic acid assay procedure (BCA protein 
assay; Pierce, IL).
7.7 Measurement of ceramide concentrations
Immature DCs (1 x 10  ^ cells/sample) were incubated in 80 pi phosphate 
buffered saline with human TNFa (200 ng/ml) in the presence or absence of either 
DETA-NO (100 pM), SNAP (200 pM) or 8-Br-cGMP (3 mM), with or without ODQ (3 
pM), then quickly shifted at 37°C. At the time-points indicated, incubation was stopped 
by the addition of 300 pi ice-cold CH3OH/CHCI3 (2/1, vol/vol). Samples were then 
supplemented with 100 pi CHCI3 and 100 pi NaCl (IM). The extracted phospholipids 
were incubated for 1 h at room temperature with 100 pU diacylglycerol kinase in the 
presence of 5 mg/ml cardiolipin, 7.5 % glucopyranoside, 1 mM diethylenetriamine 
pentaacetic acid and 10 pCi y^^P-ATP (10 mCi/ml) as described (Cifone et al., 1994). 
Under these conditions, diacylglycerol kinase is not rate limiting and full conversion of 
ceramide to ceramide phosphate is thus to be expected (Perry et al., 1999). The 
ceramide phosphates produced were separated by thin layer chromatography (Silca gel 
60, Merck, Milan, Italy) using CHCI3/CH3OH/CH3COOH (65/15/5, vol/vol/vol) as
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solvent. To determine the concentration of ceramide per sample, known amounts of 
ceramide standard were processed and loaded in parallel. The relevant spots were 
identified by autoradiography and their radioactivity estimated by microdensitometry 
using a Molecular Dynamics Imagequant apparatus (Buckinghamshire, UK).
7.8 Western blotting
Dendritic cells were incubated for 24 h in the culture medium with or without 
human TNF-a (200 ng/ml), IL-4 (1000 U/ml), GM-CSF (50 ng/ml), IFNy (100 U/ml) 
and lipopolysaccharide (LPS, 10 pg/ml) in various conbinations as described in the 
results. Cells were then collected, washed three times with cold PBS and lysed for 30 
min with a buffer containing 150 mM NaCl, 1 mM EDTA, 10% glicerolo, 50 mM 
HEPES pH 7,5, 15 mM MgCU, 1 % Triton X-100, 0.1 noM phenylmethyl 
sulphonylfluoride, 10 pg/ml leupeptin and 10 pg/ml aprotinin. The homogenates were 
centrifuged at 3000 rpm for 5 min at 4°C and the supernatant was recovered. Protein 
content in the lysates was assayed by the bicinchoninic acid procedure. After addition of 
sodium dodecyl sulfate (SDS) and P-mercaptoethanol the samples were boiled for 5 min 
and 50 pg of protein/lane were loaded into the slots of 10 % SDS polyacrylamide gels 
as described (Sciorati et al., 1997). High-efficiency transfer of proteins onto nitro­
cellulose membranes was obtained at 300 mA for 4 h at 4°C, in a buffer containing 25 
mM Tris, 192 mM glycine, 20% CH3OH, pH 8.3. After transfer, the blots were stained 
with Ponceau red. For Western blotting, the nitrocellulose membranes were incubated in 
a blocking buffer (Tris-HCl 50 mM, NaCl 150mM, Tween-20 0,05%, 5% powdered 
milk) for 1 h at room temperature, then incubated over night at 4° C with the anti-iNOS 
Ab in the same buffer under continous agitation. The next day the nitrocellulose sheets
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were processed at room temperature: the membranes were washed for 5 min with 
blocking buffer at least 5 times and incubated for 1 h with HRP-labeled goat anti-mouse 
Ab, after which the membranes were washed several times in the same buffer. 
Immunoreactive bands were revealed with Enhanced ChemiLuminescence detection 
reagent according to the manufacturer’s instructions.
7.9 Lymphocytes preparations
T cell enriched preparations were obtained as follows: PBMC (5 x 10^), were 
obtained from PPD positive or negative donors or from buffy coats (kindly provided by 
the Blood Transfusion Department of our Institution) with a standard gradient 
separation procedures on Fycoll-Paque as described before. PBMC were washed in 
RPMI 1640 medium and incubated in complete medium containing 0.5% carbonyl iron 
for 60 min at 37°C on a rotating wheel. Phagocytic cells engulfed of carbonyl iron were 
removed with a magnet as described (Burastero et al., 1990). T cell enriched population 
was separeted from residual carbonyl iron with a density Fycoll-Paque gradient and then 
washed twice in RPMI 1640 medium. With these procedures, residual monocytes 
accounted for less than 1 % of the cell preparations, as checked with anti-CD 14 mAh by 
flow cytometry (not shown).
7.10 Lymphocyte proliferation assays
For MLRs DCs, pre-treated as described above, were co-cultured at different 
ratios to 96 well flat bottom plates together with heterologous lymphocytes, which were 
maintained at the constant concentration of 10  ^ cells/well. Dendritic cells to 
lymphocytes ratios ranged from 1:1000 to 1:5. For antigen-driven proliferation assays
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DCs (2 X 10 cells/well) were incubated with autologous lymphocytes (10 cells/well) in 
the presence of 1 pg/ml PPD, 0.2 pg/ml SEB, or 1 pg/10^ cells anti-CD3 mAh. In some 
experiments, lymphocytes were stimulated either with SEB (0.2 pg/ml) on plates pre­
coated by a 3 h incubation (37°C) with anti-CD28 mAh (5 pg/ml), or on plates pre­
coated with both the anti-CD28 mAh and anti-CD3 mAh (1 pg/ml) in the presence of a 
DC-conditioned culture medium (1:1). This DC-conditioned medium was freshly 
prepared the day of the experiment by collecting supernatants conditioned for 48 h by 
the various DC preparations described above. The supernatant was filtered through a 0.2 
pm Millipore filter before use. T cell proliferation was evaluated by measuring 
incorporation of methyl-^H thymidine (0.8 pCi/well), which was added to the co­
cultures during the last 6 h. To this end cells were harvested and radioactivity measured 
using a Wallac LKB ^-counter. The results are expressed as the mean of triplicate 
cultures.
7.11 Cytokine assays
T cells were co-cultured with DCs (10  ^T cells plus 2 x 10"^  DCs), pre-treated as 
described above, on 96-well plates in 200 pi medium. IL-2 and IFN-y concentrations 
were determined in the medium 48 h after stimulation using commercially available 
ELISA kits for human IFN-y and IL-2 (R&D Systems, Space Import Export, Milan, 
Italy). IL-12p70 was measured in supernatants conditioned for 18 h by DCs pre-treated 
with or without TNF-a in the presence or absence of DETA-NO using the Quantikine 
High Sensitivity kit (detection limit 0.5 pg/ml) following the manufacturer’s 
instructions (R&D Systems).
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7.12 Measurement of nitric oxide accumulation
Nitric oxide production was measured by determining the nitrite accumulation 
from the culture medium of cells using the Griess reaction (Green et al., 1982). Standard 
curves with increasing concentrations of sodium nitrite were run in parallel.
7.13 Statistical analysis
The results are expressed as means ± SEM; n represents the number of 
individual experiments. Statistical analysis was performed using the Student’s t test for 
unpaired variables (two-tailed). The marks **, and *** in the figures panels refer to 
statistical probabilities (P) of < 0.01 and < 0.001, respectively, measured in the various 
experimental conditions as detailed in the legends to figures.
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10 LIST OF ABBREVIATIONS
APC Antigen-presenting cell
CAT Cationic amino acid transporter protein
CLA Cutaneous lymphocyte-associated antigen
CLP Common lymphoid progenitor
CMP Common myeloid progenitor
DC Dendritic cell
DETA-NO (Z)-l-[2-(2-aminoethyl)-N-(2ammonioethyl) amino]diazen-l-ium-1,2 
diolate
EAE Experimental allergic encephalomyelitis
EEC EBLl ligand chemokine
FAD Flavin adenine dinucleotide
FADD Fas-associated death domain
fMLP N-formyl-methionyl-leucyl-phenylalanine
FMN Flavin adenine mononucleotide
GM-CSF Granulocyte Macrophage Colony-Stimulating Factor
HMGBl High mobility group 1
Hsp Heat shock protein
ICD Intracellular domain
IFNy Interferon-y
IE Interleukin
ILT Immunoglobulin-like transcipt
ImDC Immature Dendritic cell
IRAK IL-lR-associated kinase
ITAM Immunoreceptor tyrosine-containing activation motif
LAK lymphokine-activated killing
L-NAME N®-nitro-L-arginine methyl ester
L-NMMA L-N°-Monomethylarginine, Acetate Salt
EPS Lipopolysaccharide
MDR-1 MDR-1-type p-glycoprotein
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MHC Major histocompatibility complex
MLR Mixed lymphocytes reaction
MMR Macrophage-mannose receptor
NCR Natural cytotoxicity receptors
NIK NF-kB-inducing kinase
NK Natural killer
NO Nitric oxide
NOS Nitric oxide synthase
ODQ H- [ 1,2,4] oxadiazolo [4,3 -a] quinoxalin-1 -one
PBMC Peripheral blood mononuclear cell
PPD Tuberculin purified protein derivative
pre-DC Dendritic cells precursor
RFI Relative fiuorescence intensity
RIP Receptor-interacting protein
SEB Staphylococcus aureus Cowen strain B
SLC Secondary-lymphoid-tissue chemokine
SNAP S-nitroso-acetylpenicillamine
SODD Inhibitory protein silencer of death domains
SRs Scavenger receptors
TCR T cell receptor
TGF-B Transforming growth factor-beta
Thl T helper lymphocyte
THB T etrahydrobiopterin
TLR Toll-like receptor
TNF-a Tumor necrosis factor alpha
TRADD TNF receptor-associated death domain
TRAF TNF-R-associated factor
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